var title_f10_38_10848="Posterior elbow dislocation";
var content_f10_38_10848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior elbow dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiographic findings. A) AP x-ray. The radial head is superimposed behind the distal humerus. There is increased cubitus valgus. The medial epicondyle has not been avulsed. B) Lateral x-ray showing that the proximal radius and ulna are both displaced posteriorly to the distal humerus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stans AA, Heinrich SD. Dislocations of the elbow. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10848=[""].join("\n");
var outline_f10_38_10848=null;
var title_f10_38_10849="Hepatitis B vaccine: Patient drug information";
var content_f10_38_10849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hepatitis B vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     see \"Hepatitis B vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"     see \"Hepatitis B vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Engerix-B&reg;;",
"     </li>",
"     <li>",
"      Recombivax HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Engerix-B&reg;;",
"     </li>",
"     <li>",
"      Recombivax HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10031425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_hepatitis_b.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11769 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.231-DF96EE1385-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10849=[""].join("\n");
var outline_f10_38_10849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178984\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031425\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=related_link\">",
"      Hepatitis B vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=related_link\">",
"      Hepatitis B vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10850="Patient information: Urinary tract infections in children (The Basics)";
var content_f10_38_10850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16963\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/35/12848\">",
"          Location of pain in pyelonephritis (kidney infection)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/51/17202\">",
"         Patient information: Blood in the urine (hematuria) in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/36/29249\">",
"         Patient information: Circumcision in baby boys (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/58/38818\">",
"         Patient information: Urinary tract infections in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Urinary tract infections in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/urinary-tract-infections-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10257721\">",
"      <span class=\"h1\">",
"       What is the urinary tract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The urinary tract is the system of organs that makes, stores, and carries urine out of the body (",
"      <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"       figure 1",
"      </a>",
"      ). The organs in the urinary tract are the:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Kidneys &ndash; The kidneys make urine.",
"       </li>",
"       <li>",
"        Ureters &ndash; The ureters are thin tubes that carry urine from the kidneys to the bladder.",
"       </li>",
"       <li>",
"        Bladder &ndash; The bladder stores urine.",
"       </li>",
"       <li>",
"        Urethra &ndash; The urethra is the tube that carries urine out of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257736\">",
"      <span class=\"h1\">",
"       What causes a urinary tract infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A urinary tract infection (or &ldquo;UTI&rdquo;) is usually caused by bacteria. Normally, bacteria are not in the urinary tract. But if they travel up the urethra and get into the bladder or kidneys, they can cause a UTI.",
"     </p>",
"     <p>",
"      Children can have a higher chance of getting a UTI if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Their urinary system didn&rsquo;t form normally before birth.",
"       </li>",
"       <li>",
"        Their bladder doesn&rsquo;t work normally.",
"       </li>",
"       <li>",
"        They are boys and are not circumcised. Boys who are circumcised have had surgery to remove the skin that covers the tip of the penis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257751\">",
"      <span class=\"h1\">",
"       What are the symptoms of a UTI?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on a child&rsquo;s age.",
"     </p>",
"     <p>",
"      Children younger than 2 years old can have 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever &ndash; This might be a child&rsquo;s only symptom.",
"       </li>",
"       <li>",
"        Vomiting or diarrhea",
"       </li>",
"       <li>",
"        Acting fussy",
"       </li>",
"       <li>",
"        Not feeding well",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children age 2 years and older can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain or a burning feeling when they urinate",
"       </li>",
"       <li>",
"        A need to urinate more often than usual",
"       </li>",
"       <li>",
"        Pain in the lower belly or on the sides of the back (",
"        <a class=\"graphic graphic_figure graphicRef54658 \" href=\"UTD.htm?12/35/12848\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257766\">",
"      <span class=\"h1\">",
"       Is there a test for a UTI?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for a UTI, the doctor or nurse will do tests on your child&rsquo;s urine. To give a urine sample, your child will need to urinate into a container at the doctor&rsquo;s office.",
"     </p>",
"     <p>",
"      If your child is not toilet trained, the doctor or nurse can get a sample of urine from your child&rsquo;s bladder. He or she will put a thin tube in your child&rsquo;s urethra and up into the bladder to drain a sample of urine. Then he or she will remove the tube and test the urine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257781\">",
"      <span class=\"h1\">",
"       How are UTIs treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;UTIs are treated with antibiotic medicines. These medicines kill the bacteria causing the infection.",
"     </p>",
"     <p>",
"      Your child&rsquo;s symptoms should begin to improve within 1 to 2 days of starting the medicine. It is important to have your child take the medicine exactly as directed. If he or she doesn&rsquo;t, the infection could come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257796\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call the doctor or nurse if your child&rsquo;s symptoms don&rsquo;t get better or get worse.",
"     </p>",
"     <p>",
"      You should also call if your child gets symptoms of another UTI in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257811\">",
"      <span class=\"h1\">",
"       What if my child gets UTIs a lot?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child gets UTIs a lot, your child&rsquo;s doctor might recommend that your child take an antibiotic every day. This can help prevent him or her from getting more UTIs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10257826\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=see_link\">",
"       Patient information: Circumcision in baby boys (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       Patient information: Urinary tract infections in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/38/10850?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16963 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10850=[""].join("\n");
var outline_f10_38_10850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257721\">",
"      What is the urinary tract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257736\">",
"      What causes a urinary tract infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257751\">",
"      What are the symptoms of a UTI?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257766\">",
"      Is there a test for a UTI?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257781\">",
"      How are UTIs treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257796\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257811\">",
"      What if my child gets UTIs a lot?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10257826\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/35/12848\">",
"       Location of pain in pyelonephritis (kidney infection)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=related_link\">",
"      Patient information: Circumcision in baby boys (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10851="Neonatal gastroschisis 3";
var content_f10_38_10851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonatal gastroschisis 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classic appearing gastroschisis with the abdominal wall defect to the right of the cord insertion (the yellow clamp is on the umbilical cord). Loops of small bowel can be noted with one area of dilation at the base of the mass. The bowel dilation was a \"new finding\" during ultrasound examination and was the indication for delivery (37 weeks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO and Tamara L Bradshaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10851=[""].join("\n");
var outline_f10_38_10851=null;
var title_f10_38_10852="Iodine in the treatment of hyperthyroidism";
var content_f10_38_10852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iodine in the treatment of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10852/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10852/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10852/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10852/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10852/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10852/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10852/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine solutions, such as saturated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide solutions",
"    </a>",
"    (SSKI) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=see_link\">",
"     potassium iodide-iodine",
"    </a>",
"    (Lugol's solution), replaced burnt sponge extract in the 19",
"    <sup>",
"     th",
"    </sup>",
"    century as treatment for endemic goiter. By extension, they were sometimes used to treat Graves&rsquo; disease, but by the end of the century they were considered to be a dangerous form of therapy. They returned to favor in the 1920s as preoperative treatment for hyperthyroidism and were for a time in the 1930s thought to be useful as the sole therapy for mild hyperthyroidism. Today, iodine continues to have a minor role in the treatment of hyperthyroidism.",
"   </p>",
"   <p>",
"    The role of iodine in the treatment of hyperthyroidism will be reviewed here. The treatment of hyperthyroidism in general is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine has several effects on thyroid function. In hyperthyroid patients, iodine acutely inhibits hormonal secretion within hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/1\">",
"     1",
"    </a>",
"    ], but the responsible mechanisms are uncertain. This is the most acute effect of iodine on thyroid status, occurring within one to two days of the start of therapy.",
"   </p>",
"   <p>",
"    A second effect involves inhibition of thyroid hormone synthesis. In normal subjects, the administration of pharmacologic amounts of iodine leads to temporary inhibition of iodine organification in the thyroid gland, thereby diminishing thyroid hormone biosynthesis, a phenomenon called the Wolff-Chaikoff effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/2\">",
"     2",
"    </a>",
"    ]. However, within two to four weeks of continued exposure to excess iodine, organification and thyroid hormone biosynthesis resume in a normal fashion. This is called escape from the Wolff-Chaikoff effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with autoimmune thyroid disease, there is abnormal autoregulation of iodine economy. Iodine-induced blockade of iodine organification persists and can result in or exacerbate hypothyroidism in patients with Hashimoto's thyroiditis, or ameliorate hyperthyroidism in Graves&rsquo; disease. Thus, patients with Graves&rsquo; hyperthyroidism are more sensitive to the inhibitory effect of pharmacologic doses of iodine than normal subjects, making iodine treatment effective in some patients. In addition, pharmacologic amounts of iodine may acutely ameliorate hyperthyroidism by blocking thyroid hormone release.",
"   </p>",
"   <p>",
"    The overall inhibitory effect of iodine on serum thyroid hormone concentrations is maximal after about 10 days of treatment. However, the inhibitory effect is transient and is often followed by a return to high concentrations, although the benefit may be more prolonged, especially in patients who have received radioiodine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5852546\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine is primarily used in the short term (one to two weeks) for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the preoperative preparation for thyroidectomy in Graves' disease &ndash; Iodine (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=see_link\">",
"       potassium iodide-iodine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide solutions",
"      </a>",
"      ) is given for up to 10 days to decrease gland vascularity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/4,5\">",
"       4,5",
"      </a>",
"      ] and, in patients who are not euthyroid, to lower serum thyroid hormone concentrations. In hyperthyroid patients with toxic adenoma or toxic nodular goiter, or patients with Graves&rsquo; disease in regions with iodine deficiency, iodine administration may exacerbate hyperthyroidism because the iodine provides more substrate for new hormone synthesis. These patients should not be routinely treated with iodine to reduce gland vascularity preoperatively and when iodine is used to help lower serum thyroid hormone concentrations, iodine should not be administered until one hour",
"      <strong>",
"       after",
"      </strong>",
"      a thionamide has been given to block thyroid hormone synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link&amp;anchor=H6#H6\">",
"       \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Preoperative preparation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with severe hyperthyroidism or thyroid storm &ndash; The administration of iodine should be delayed for at least one hour",
"      <strong>",
"       after",
"      </strong>",
"      &nbsp;thionamide administration to prevent the iodine from being used as substrate for new hormone synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link&amp;anchor=H6#H6\">",
"       \"Thyroid storm\", section on 'Iodine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As adjunctive therapy after administration of radioiodine in Graves' disease, especially in patients who wish to avoid taking or who are allergic to thionamides &ndash; SSKI, given daily beginning one week after radioiodine administration, normalizes thyroid function several weeks earlier than in patients treated with radioiodine alone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/6\">",
"       6",
"      </a>",
"      ]. Iodine can also be given months after radioiodine administration to ameliorate mild persistent hyperthyroidism and to delay or prevent the need for a second radioiodine dose.",
"     </li>",
"     <li>",
"      As adjunctive therapy with antithyroid drug therapy in Graves&rsquo; disease &ndash; Low dose (50 mg)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      tablets added to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      results in normal free T4 levels by two weeks in 54 and 59 percent of patients treated with 15 or 30 mg methimazole, respectively, compared with 27 and 29 percent of patients treated with 15 or 30 mg methimazole alone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IODINE PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following iodine preparations can be used in the treatment of hyperthyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       Potassium iodide",
"      </a>",
"      (SSKI [super saturated KI] about 35 to 50 mg iodine per drop and KI about 24",
"      <span class=\"nowrap\">",
"       mg/drop)",
"      </span>",
"      is usually given orally in a dose of one to five drops three times daily when used in the preoperative preparation for thyroidectomy in Graves&rsquo; disease, five drops given four times daily for thyroid storm, three drops given twice daily as adjunctive therapy following radioiodine, and smaller doses for treating mild hyperthyroidism. KI tablets 130 mg are available in the United States (containing 100 mg iodide).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/36/35396?source=see_link\">",
"       Potassium iodide-iodine",
"      </a>",
"      (Lugol's solution [5 to 8 mg iodine per drop]) is usually given orally in a dose of three to five drops three times daily when used in the preoperative preparation for thyroidectomy in Graves&rsquo; disease and 10 drops given three times daily for thyroid storm.",
"     </li>",
"     <li>",
"      For patients unable to take oral medication, Lugol&rsquo;s solution can be added directly to intravenous fluids because it is sterile [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/8\">",
"       8",
"      </a>",
"      ]. An alternative is to give the iodine solution per rectum [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10852/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3460725\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iodine-containing solutions acutely block the release of T4 and T3 from the gland within hours. In addition, administration of pharmacologic amounts of iodine inhibits iodine organification in the thyroid gland. In patients with Graves&rsquo; disease, the iodine-induced blockade of organification persists and can result in amelioration of hyperthyroidism. The overall inhibitory effect of iodine on serum thyroid hormone concentrations is maximal after about 10 days of treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While largely supplanted by thionamide drugs and radioactive iodine, pharmacologic doses of iodine can still be recommended for the short-term management of hyperthyroid patients in whom rapid restoration of the euthyroid state is beneficial. Indications include the preoperative preparation for patients with Graves&rsquo; disease, where iodine has the additional benefit of decreasing thyroid gland vascularity, thyroid storm, or as adjunctive therapy after administration of radioiodine in Graves' disease. (See",
"      <a class=\"local\" href=\"#H5852546\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine-containing agents include Lugol&rsquo;s solution and SSKI. Dosing varies with the indication. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Iodine preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with thyroid storm, hyperfunctioning adenoma, multinodular goiter, or Graves&rsquo; disease in regions with iodine deficiency, the administration of iodine should be delayed for at least one hour",
"      <strong>",
"       after",
"      </strong>",
"      &nbsp;thionamide administration to prevent the iodine from being used as substrate for new hormone synthesis. (See",
"      <a class=\"local\" href=\"#H5852546\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/1\">",
"      Emerson CH, Anderson AJ, Howard WJ, Utiger RD. Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 1975; 40:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/2\">",
"      WOLFF J, CHAIKOFF IL. The temporary nature of the inhibitory action of excess iodine on organic iodine synthesis in the normal thyroid. Endocrinology 1949; 45:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/3\">",
"      Philippou G, Koutras DA, Piperingos G, et al. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf) 1992; 36:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/4\">",
"      Marigold JH, Morgan AK, Earle DJ, et al. Lugol's iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg 1985; 72:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/5\">",
"      Erbil Y, Ozluk Y, Giri M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 2007; 92:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/6\">",
"      Ross DS, Daniels GH, De Stefano P, et al. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/7\">",
"      Takata K, Amino N, Kubota S, et al. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Clin Endocrinol (Oxf) 2010; 72:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/8\">",
"      Benua RS, Becker DV, Hurley JR. Thyroid storm. Curr Ther Endocrinol Metab 1994; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10852/abstract/9\">",
"      Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 1995; 5:403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7878 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10852=[""].join("\n");
var outline_f10_38_10852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3460725\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5852546\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IODINE PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3460725\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10853="Concealed accessory pathways";
var content_f10_38_10853=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Concealed accessory pathways",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10853/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10853/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal electrical activation of the ventricles follows a precisely defined pattern. After an impulse emerges from the atrioventricular (AV) node, it traverses the His bundle, and propagates down the bundle branches and the fascicles to the terminal Purkinje fibers and, ultimately, the ventricular myocardium.",
"   </p>",
"   <p>",
"    The normal temporal and spatial sequence of atrial and ventricular activation can be altered by anomalous conduction via accessory pathways (APs), also called bypass tracts, between the atria and ventricles. APs frequently form the substrate for a supraventricular tachycardia (SVT) known as atrioventricular reentrant tachycardia (AVRT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most APs are capable of antegrade conduction from atrium to ventricle, and such pathways often produce such characteristic ECG abnormalities as ventricular preexcitation and a shortened PR interval. These findings are referred to as a Wolff-Parkinson-White (WPW) ECG pattern, and patients with such findings who also have episodes of AVRT have the WPW syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some APs do not conduct antegrade to the ventricles, but are able to conduct retrograde from the ventricles to the atria. Retrograde conduction can be seen following ventricular pacing or ventricular ectopy, and it can form the retrograde arm of an orthodromic AVRT circuit. Because there is no antegrade conduction over the AP, the characteristic WPW ECG pattern is absent and, therefore, these pathways are termed \"concealed accessory pathways\".",
"   </p>",
"   <p>",
"    The pathophysiology, epidemiology and management of concealed APs will be reviewed here. The electrocardiographic and pathophysiologic characteristics of conventional APs, and detailed discussions of arrhythmias associated with APs and the approach to the management of such arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the more common APs that are capable of both antegrade and retrograde conduction, concealed APs consist of strands of myocardium that course through the epicardial fat. These strands insert into the ventricular myocardium just beyond the annulus of the mitral valve or, less often, the tricuspid valve. The vast majority of concealed accessory pathways are left-sided [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    APs are congenital in origin, resulting from failure of resorption of the myocardial syncytium at the annulus fibrosis of the atrioventricular valves during fetal development.",
"   </p>",
"   <p>",
"    It is estimated that 60 to 75 percent of APs exhibit bidirectional conduction, 5 to 27 percent conduct only antegradely, and 17 to 37 percent conduct only retrogradely (ie, are concealed) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nondecremental conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concealed APs usually exhibit nondecremental retrograde conduction (ie, VA conduction does not slow at faster rates) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This ability to conduct without decrementing at faster rates allows these APs to function as the retrograde arm of sustained reentrant tachyarrhythmias (ie, orthodromic AVRT). Occasionally, concealed APs exhibit decremental retrograde conduction (ie, conduction velocities slow at increased rates). Such decremental concealed APs are associated with an unusual SVT called the permanent form of junctional reciprocating tachycardia (PJRT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of antegrade block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism responsible for unidirectional conduction along the AP is not clear. \"Impedance mismatch\" has been proposed, resulting from the marked differences in diameter of the conducting tissues at the atrial-AP and AP-ventricular interfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. According to this hypothesis, the small current generated by the strands of myocardium constituting the AP is insufficient to depolarize the much larger ventricular muscle mass. Support for this hypothesis comes from a series including 126 patients with either a manifest or concealed AP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/1\">",
"     1",
"    </a>",
"    ]. Potentials were recorded from the AP in each patient; the site of block was localized to the AP-ventricular interface in the majority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermittent antegrade conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, an AP that appears to be concealed may be capable of antegrade conduction in some situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If AV nodal conduction is enhanced",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the AP is left lateral (ie, far from the sinus node), conduction may proceed over the normal AV node-His Purkinje system more quickly than over the AP. In these cases, antegrade AP conduction occurs, but is not manifest on the surface ECG. Transient blockade of AV nodal conduction with adenosine may expose the \"concealed\" pathway.",
"     </li>",
"     <li>",
"      In some patients with left free wall accessory pathways, pacing the left atrium via the coronary sinus, in an area closer to the AP, may be necessary to bring out antegrade AP conduction and overt preexcitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent SVT that occurs in patients with concealed APs is an orthodromic AVRT. The range of tachyarrhythmias associated with both manifest and concealed APs is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adenosine-5'-triphosphate to induce SVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of adenosine-5'-triphosphate (ATP) is useful for the noninvasive diagnosis of dual AV nodal pathways as a result of AV nodal conduction delay in the slow pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/7\">",
"     7",
"    </a>",
"    ]. ATP is not currently available in the United States.",
"   </p>",
"   <p>",
"    The ability of ATP to slow AV nodal conduction may make it useful for inducing AVRT in patients with a concealed AP. Such a provocative test could be useful in a patient with symptoms of SVT but no evidence of preexcitation on a baseline ECG. This approach was examined in 34 patients with inducible sustained AVRT involving a concealed AP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/8\">",
"     8",
"    </a>",
"    ]. AV reentrant beats or AVRT, which were preceded by a slight increase in PR interval (&lt;50 msec), occurred in 73 percent of the patients in the trial and in none of 27 control patients. In addition, 21 percent of patients also had evidence of dual AV nodal pathways. The occurrence of AV reentrant beats or AVRT after the administration of ATP correlated with the induction of AVRT during electrophysiologic study with a sensitivity, specificity, and positive and negative predictive value of 73, 100, 100, and 100 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true prevalence of concealed APs is unknown. Because the concealed AP is only \"expressed\" during AVRT, its presence cannot be established with an ECG during sinus rhythm. Thus, only patients who are sufficiently bothered by symptoms from associated arrhythmias to undergo diagnostic electrophysiologic studies ever have concealed APs diagnosed. Among patients with symptomatic SVT presenting for catheter ablation, the prevalence of concealed APs is approximately 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    APs that conduct antegrade generate characteristic abnormalities on a baseline ECG (ie, a Wolff-Parkinson-White pattern). Thus, in contrast to concealed APs, the prevalence of such APs can be estimated from series of ECGs in the general population. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy for concealed APs is the prevention of symptomatic tachyarrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptomatic arrhythmias due to concealed APs are managed like patients with other types of SVT unrelated to WPW (eg, AVNRT); either catheter ablation or treatment with an AV nodal blocking agent (beta blocker,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ) is reasonable initial therapy. Patient preference for chronic medical therapy versus an interventional procedure is an important component in selecting a therapeutic strategy. In contrast, patients with symptomatic WPW (ie, with APs that are capable of antegrade conduction, evidenced by preexcitation on the baseline ECG) are recommended catheter ablation rather than medical therapy, because of the potential for rapidly pre-excited atrial fibrillation or flutter and sudden cardiac death.",
"     </li>",
"     <li>",
"      Patients with rare, well-tolerated arrhythmias can be managed conservatively with observation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific recommendations regarding the management of concealed APs are included in broader discussions of the treatment of tachyarrhythmias associated with the WPW syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy of concealed AP ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall success rate for radiofrequency catheter ablation of APs varies from 93 to 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. However, these studies include patients with all types of APs and do not separately report the outcome of those with only a concealed pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although specific data regarding radiofrequency ablation of concealed pathways are limited, the following observations suggest that success rates similar to those for conventional APs can be expected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series that included 100 patients with concealed APs, the procedural success for ablating these concealed pathways was 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The majority of concealed APs are left-sided [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/1\">",
"       1",
"      </a>",
"      ]. In patients with conventional APs, both acute success rates and long term recurrence rates are better for ablation of left-sided pathways than for right-sided pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10853/abstract/12,15\">",
"       12,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ablation complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complication rates associated with radiofrequency ablation in patients with concealed APs are similar to those for catheter ablation of SVT in general. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, since left heart access is frequently required for ablation of a concealed pathway, risks relating to obtaining left heart access via a retrograde aortic or transseptal approach must be carefully considered. These include cardiac trauma (myocardial perforation, infarction, valvular damage) and a small risk of systemic thromboembolism.",
"   </p>",
"   <p>",
"    In many patients with SVT, the distinction between AVNRT and AVRT due to a concealed pathway cannot be established prior to the diagnostic electrophysiologic study. Thus, the attendant risks of left-sided ablation should be discussed with all patients prior to the electrophysiology study, which is done initially in a combined procedure with catheter ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concealed accessory pathways (APs) are strands of myocardium connecting the atrium and ventricle, bridging the mitral or, less commonly, the tricuspid annulus. These structures are characterized by the ability to conduct electrical impulses retrograde from the ventricles to the atria, but an inability to conduct antegrade from the atria to the ventricles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 17 to 37 percent of all APs are concealed, and orthodromic AVRT due to concealed APs is present in up to 15 percent of patients with SVT referred for catheter ablation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of concealed APs are left-sided. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most concealed APs exhibit nondecremental retrograde conduction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nondecremental conduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tachyarrhythmias due to concealed APs are managed similarly to those SVTs associated with conventional APs, and frequent symptomatic arrhythmias are most commonly treated with catheter ablation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/1\">",
"      Kuck KH, Friday KJ, Kunze KP, et al. Sites of conduction block in accessory atrioventricular pathways. Basis for concealed accessory pathways. Circulation 1990; 82:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/2\">",
"      Miller JM. Therapy of Wolff-Parkinson-White syndrome and concealed bypass tracts: Part I. J Cardiovasc Electrophysiol 1996; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/3\">",
"      Ross DL, Uther JB. Diagnosis of concealed accessory pathways in supraventricular tachycardia. Pacing Clin Electrophysiol 1984; 7:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/4\">",
"      Gillette PC. Concealed anomalous cardiac conduction pathways: a frequent cause of supraventricular tachycardia. Am J Cardiol 1977; 40:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/5\">",
"      De la Fuente D, Sasyniuk B, Moe GK. Conduction through a narrow isthmus in isolated canine atrial tissue. A model of the W-P-W syndrome. Circulation 1971; 44:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/6\">",
"      Inoue H, Zipes DP. Conduction over an isthmus of atrial myocardium in vivo: a possible model of Wolff-Parkinson-White syndrome. Circulation 1987; 76:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/7\">",
"      Belhassen B. Adenosine triphosphate in cardiac arrhythmias: from therapeutic to diagnostic use. Pacing Clin Electrophysiol 2002; 25:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/8\">",
"      Belhassen B, Fish R, Viskin S, et al. Adenosine-5'-triphosphate test for the noninvasive diagnosis of concealed accessory pathway. J Am Coll Cardiol 2000; 36:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/9\">",
"      Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991; 324:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/10\">",
"      Kay GN, Epstein AE, Dailey SM, Plumb VJ. Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol 1993; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/11\">",
"      Farshidi A, Josephson ME, Horowitz LN. Electrophysiologic characteristics of concealed bypass tracts: clinical and electrocardiographic correlates. Am J Cardiol 1978; 41:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/12\">",
"      Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation 1999; 99:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/13\">",
"      Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/14\">",
"      Brugada J, Garc&iacute;a-Bolao I, Figueiredo M, et al. Radiofrequency ablation of concealed left free-wall accessory pathways without coronary sinus catheterization: results in 100 consecutive patients. J Cardiovasc Electrophysiol 1997; 8:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10853/abstract/15\">",
"      Langberg JJ, Calkins H, Kim YN, et al. Recurrence of conduction in accessory atrioventricular connections after initially successful radiofrequency catheter ablation. J Am Coll Cardiol 1992; 19:1588.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1021 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10853=[""].join("\n");
var outline_f10_38_10853=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nondecremental conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of antegrade block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermittent antegrade conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adenosine-5'-triphosphate to induce SVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy of concealed AP ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ablation complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=related_link\">",
"      Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10854="Regulators and receptors of the complement system";
var content_f10_38_10854=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Regulators and receptors of the complement system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10854/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10854/contributors\">",
"     M Kathryn Liszewski, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10854/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10854/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10854/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10854/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10854/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10854/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10854/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise control of the complement system is necessary because of its potent proinflammatory and cellular destructive capabilities. The regulation of the complement system will be reviewed here. In order to fully comprehend the functions of the various regulatory proteins, it is helpful to be familiar with the complement pathways, which are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link\">",
"     \"Complement pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLEMENT REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly one-half of all complement proteins serve a regulatory function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The goal of regulation is to prevent complement damage to normal host tissue (inappropriate or wrong target) and fluid phase activation (no target) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/3\">",
"     3",
"    </a>",
"    ]. Deficiencies of control proteins lead to excessive complement activation and significant morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regulatory proteins inhibit the system by destabilizing activation complexes and by mediating specific proteolytic cleavages that degrade activation-derived fragments. The complement system is regulated at the following critical steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activation or initiation",
"     </li>",
"     <li>",
"      Amplification (convertase formation)",
"     </li>",
"     <li>",
"      Membrane attack",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various complement regulatory proteins, their location in the plasma or in cell membranes, their function, and their substrate(s) are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71885 \" href=\"UTD.htm?32/25/33180\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Control of activation/initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the classical pathway, C1 inhibitor prevents excessive complement activation on a target and activation in plasma. C1 inhibitor blocks the active site of C1r and C1s, and is a member of the \"serpin\" superfamily of serine protease inhibitors (",
"    <a class=\"graphic graphic_figure graphicRef72648 \" href=\"UTD.htm?2/56/2950\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    C1 inhibitor performs a similar function in the analogous lectin pathway. This pathway has an activation scheme analogous to that of the classical complement pathway, but lectins substitute for antibodies and a lectin-associated protease replaces C1r and C1s. The lectins bind sugar residues on the microbial surface; their associated mannose binding associated serine proteases (MASPs) subsequently cleave C4 and C2. C1 inhibitor blocks the active sites of these MASPs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link&amp;anchor=H13#H13\">",
"     \"Inherited disorders of the complement system\", section on 'Lectin pathway deficiencies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    C1 inhibitor has a variety of biologic functions, in addition to control of complement activation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1 inhibitor regulates three other interrelated pathways: the coagulation (contact), fibrinolytic, and kinin-generating systems. The role of C1 inhibitor in limiting the generation of kinins is believed to be central to the pathogenesis of hereditary angioedema, a condition caused by a deficit or dysfunction of C1 inhibitor. Hereditary angioedema is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In animals, treatment with purified C1 inhibitor improves survival in experimental models of bacterial- and endotoxin-induced septic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. The effect was also demonstrated with inactivated C1 inhibitor, suggesting that inhibition of the complement system was not the primary mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/7\">",
"       7",
"      </a>",
"      ]. The use of C1 inhibitor therapy in human sepsis has not yet been studied. The role of complement in the pathophysiology of sepsis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"       \"Pathophysiology of sepsis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Control of amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alternative and classical pathway C3 convertases are powerful amplifiers of the complement system. The convertase steps of both pathways are regulated by a family of complement binding proteins that includes (",
"    <a class=\"graphic graphic_table graphicRef71885 \" href=\"UTD.htm?32/25/33180\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membrane proteins &mdash; Decay accelerating factor (DAF; CD55) and membrane cofactor protein (MCP; CD46)",
"     </li>",
"     <li>",
"      Plasma proteins &mdash; C4-binding protein (C4bp), which regulates C4b, and the classical and lectin pathway convertases and factor H, which regulates C3b and the alternative pathway convertases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These proteins function in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By disassembling or disassociating the convertases (known as decay accelerating activity)",
"     </li>",
"     <li>",
"      By limited proteolytic cleavage of C4b and C3b; this requires collaboration with a plasma serine protease factor I and is known as cofactor activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These widely expressed membrane regulators inhibit complement on",
"    <strong>",
"     host",
"    </strong>",
"    tissue while the plasma inhibitors primarily prevent activation in the fluid phase. However, at sites of injury, the plasma inhibitors can interact with structures, such as the exposed basement membrane. Anionic or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding sites in factor H and C4bp allow those plasma regulators, in essence, to act like a membrane protein at inflammatory sites and in areas of cellular injury (eg, apoptotic and necrotic cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Control of membrane attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The membrane attack complex (MAC) is also regulated both in the fluid phase and on cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/8\">",
"     8",
"    </a>",
"    ]. Control in plasma prevents diffusion from the activation site. S-protein (also known as vitronectin) controls fluid-phase MAC by binding to a site on the C5b-7 complex, thereby preventing its insertion into cell membranes. MACs that deposit on self tissue are inhibited by CD59 (also called protectin, membrane inhibitor of reactive lysis, or membrane attack complex inhibitory factor). This widely expressed glycolipid anchored-membrane protein has binding sites for both C8 and C9 and thereby inhibits the final steps of MAC assembly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Control of anaphylatoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;When complement proteins C3, C4, and C5 are activated, small peptides of 74 to 77 amino acids in length are released from the amino-terminus of the alpha chain. The resulting anaphylatoxins (C3a, C4a, and C5a) are inactivated by a plasma enzyme called carboxypeptidase-N that removes the carboxyl-terminal arginyl residue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLEMENT RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many host cells, especially peripheral blood cells, possess receptors for complement activation fragments that promote the adherence and ingestion of microorganisms and immune complexes (",
"    <a class=\"graphic graphic_table graphicRef58974 \" href=\"UTD.htm?30/59/31675\">",
"     table 2",
"    </a>",
"    ). Upon engagement, these receptors, which are expressed on most inflammatory and immunocompetent cells, induce cellular responses that trigger inflammatory and immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complement receptor 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most peripheral blood cells possess complement receptor 1 (also called CR1, CD35,",
"    <span class=\"nowrap\">",
"     C3b/C4b,",
"    </span>",
"    or immune adherence receptor). CR1 plays a critical role in the clearance of C4b- and C3b-coated particles (eg, immune complexes) on which the complement system has been activated. Deposition of C3b and C4b on a target is particularly efficacious in promoting attachment to cells bearing complement receptors. This phenomenon is known as immune adherence.",
"   </p>",
"   <p>",
"    Erythrocytes express approximately 500 copies of CR1 per cell. This allows the erythrocyte to bind to intravascular immune complexes and to serve as a vehicle (taxi) that transports immune complexes to the liver and spleen. Hepatic and splenic macrophages then \"clear\" such immune complexes by stripping them from the erythrocyte, destroying the antigen (often viruses or bacteria), and facilitating an immune response (antigen presentation). The erythrocyte may then return to the circulation for another round of immune complex clearance (",
"    <a class=\"graphic graphic_figure graphicRef72648 \" href=\"UTD.htm?2/56/2950\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The function of CR1 depends in part upon the type of cell on which it is expressed. As noted above, the primary function of CR1 on erythrocytes is to clear circulating immune complexes. In comparison, CR1 on neutrophils and monocytes binds C3b or C4b bearing immune complexes, resulting in a cellular response that often includes internalization and digestion. In addition, CR1 is expressed on B-lymphocytes, a subset of T-lymphocytes, and on follicular-dendritic cells where it facilitates the localization of complement-bearing antigens to lymphoid follicles. On peripheral blood cells, CR1 is primarily an immune adherence receptor. It may also serve a regulatory role by preventing further complement activation and by converting C3b to inactivation fragments (iC3b and C3dg), which then engage additional complement receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complement receptor 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement receptor 2 (also called CR2, C3d or C3dg receptor, and CD21) is expressed on B lymphocytes, follicular dendritic cells, epithelial cells in the pharynx and upper airway, and in low amounts on peripheral blood T cells; it is not found on monocytes, granulocytes, or erythrocytes.",
"   </p>",
"   <p>",
"    CR2 serves to localize complement-bearing immune complexes to B lymphocyte-rich areas of the spleen and lymph nodes. In this way, CR2, as well as CR1, may promote antigen-driven activation of B cells. This \"adjuvant\" function of the complement system is being exploited by attaching C3 fragments to vaccines in order to enhance their antigenicity. CR2, through its association with other membrane proteins, is also an important co-receptor in the signaling of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/12\">",
"     12",
"    </a>",
"    ]. CR2 is also the receptor for the Epstein-Barr virus (EBV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with the rare heritable disorder X-linked agammaglobulinemia lack mature B lymphocytes. Consequently, EBV cannot infect the B cells of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=see_link\">",
"     \"Agammaglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complement receptor 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement receptor 3 (also called CR3 and",
"    <span class=\"nowrap\">",
"     CD11b/18)",
"    </span>",
"    binds and promotes the opsonization of particles bearing fragments of C3, especially iC3b. CR3 (also called Mac-1) is present on",
"    <span class=\"nowrap\">",
"     macrophages/monocytes",
"    </span>",
"    and certain lymphocytes, and is part of the integrin family of adherence-promoting proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CR3 promotes ingestion. Deficiency of CR3 is associated with delayed separation of the umbilical cord, omphalitis, and severe childhood infections. This disorder is known as leukocyte adhesion deficiency syndrome-I. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"     \"Leukocyte adhesion deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since immune complexes possess varying quantities of C3-derived fragments (C3b, iC3b, C3dg, and C3d), multiple complement receptors usually cooperate to help clear immune complexes and facilitate responses to antigens. For example, CR1 promotes initial adherence, CR3 facilitates internalization, and CR2 transmits cellular signals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complement receptor 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement receptor 4 (CR4;",
"    <span class=\"nowrap\">",
"     CD11c/18)",
"    </span>",
"    has a similar function and tissue distribution as CR3. However, CR4 may also play an important role in neutrophil and monocyte adhesion to endothelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Receptors for C5a and C3a",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system can be engaged in a few seconds, and it is therefore likely that the earliest responses to microbes and tissue damage involve liberation of C3a, C5a, and interaction with their respective receptors to trigger the acute inflammatory reaction. C5a is a major chemotactic factor for neutrophils. Both C3a and C5a \"activate\" a wide variety of cell types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     C5a receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C5a receptor is prominently expressed on neutrophils, macrophages, mast cells, and basophils. The C5a receptor is a chemotactic factor for neutrophils and monocytes, and causes release of their granular constituents. The C5a receptor is also expressed on a wide variety of epithelial and endothelial cells.",
"   </p>",
"   <p>",
"    C5a has a spasmogenic effect upon various tissues by a direct action on smooth muscle cells bearing C5a receptors or secondarily by the release of mediators from mast cells. The C5a receptor belongs to the rhodopsin superfamily of seven transmembrane proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binding of C5a to its receptor may play a role in end-organ damage during sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/15\">",
"     15",
"    </a>",
"    ]. This was illustrated in an animal model of intraabdominal infection in which C5a receptor upregulation was found in lung, liver, kidney and heart soon after onset of sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/16\">",
"     16",
"    </a>",
"    ]. Administration of antibodies that blocked activation of C5a receptor was associated with improved survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The binding of C5a to its receptor may also provide a mechanism by which the complement- and immunoglobulin-activated inflammatory systems interact. In a mouse model, binding of C5a to its receptor resulted in upregulation of Fc gamma receptors. Binding of immune complexes to Fcgamma receptors, in turn, lead to generation of more C5a, thus establishing a positive feedback loop [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/17\">",
"     17",
"    </a>",
"    ]. This type of interaction also may be important in the pathogenesis of autoimmune diseases mediated by autoantibodies and immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     C3a receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The C3a receptor's major role appears to be in activating cells at sites of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/19\">",
"     19",
"    </a>",
"    ]. It is a member of the same G-coupled superfamily as the C5a receptor and has a broad tissue distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Receptors for C3a are present on endothelial, epithelial and many types of peripheral blood cells including neutrophils, monocytes, most lymphocytes, and basophils. Mast cell and basophil degranulation (like with the C5a receptor) is mediated by C3a engaging its receptor on these cell types. Variations in this receptor may affect susceptibility to asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10854/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receptors for C1q and factor H have been noted on such cells as neutrophils, monocytes, and B cells. Their function is not as clearly defined as those described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precise control of the complement system is necessary because of its potent proinflammatory and cellular destructive capabilities. Nearly one-half of all complement proteins serve a regulatory function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Complement regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of regulation is to prevent complement damage to healthy host tissue (inappropriate or wrong target) and fluid phase activation (no target). Deficiencies of inhibitory proteins lead to excessive complement activation and significant morbidity and mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complement pathways are regulated at each important step: activation, amplification (convertase formation), and membrane attack (",
"      <a class=\"graphic graphic_table graphicRef71885 \" href=\"UTD.htm?32/25/33180\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Complement regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Receptors for complement activation fragments are expressed on many host cells, including peripheral blood cells, endothelial and epithelial cells. Receptors for C4b and C3b are present on most cells of the immune system where they promote pathogen destruction and the adaptive immune response. Receptors for C3a and C5a are widely distributed where they trigger the local inflammatory response (innate immunity) and also cell activation to prepare for the adaptive immune response. These receptors promote the adherence and ingestion of microorganisms and immune complexes (",
"      <a class=\"graphic graphic_table graphicRef58974 \" href=\"UTD.htm?30/59/31675\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complement receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiencies of certain complement receptors, such as CR3, result in severe infections in childhood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=see_link\">",
"       \"Leukocyte adhesion deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/1\">",
"      Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/2\">",
"      Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/3\">",
"      Sj&ouml;berg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/4\">",
"      Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/5\">",
"      Giebler R, Schmidt U, Koch S, et al. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999; 27:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/6\">",
"      Liu D, Cai S, Gu X, et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/7\">",
"      Liu D, Lu F, Qin G, et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179:3966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/8\">",
"      Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/9\">",
"      Gullstrand B, M&aring;rtensson U, Sturfelt G, et al. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol 2009; 156:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/10\">",
"      K&ouml;hl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/11\">",
"      Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998; 16:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/12\">",
"      Erdei A, F&uuml;st G, Gergely J. The role of C3 in the immune response. Immunol Today 1991; 12:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/13\">",
"      Faulkner GC, Burrows SR, Khanna R, et al. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol 1999; 73:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/14\">",
"      Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/15\">",
"      Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004; 4:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/16\">",
"      Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/17\">",
"      Kumar V, Ali SR, Konrad S, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006; 116:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/18\">",
"      Atkinson JP. C5a and Fcgamma receptors: a mutual admiration society. J Clin Invest 2006; 116:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/19\">",
"      Boos L, Campbell IL, Ames R, et al. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol 2004; 173:4708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/20\">",
"      Crass T, Raffetseder U, Martin U, et al. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 1996; 26:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/21\">",
"      Ischenko A, Sayah S, Patte C, et al. Expression of a functional anaphylatoxin C3a receptor by astrocytes. J Neurochem 1998; 71:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10854/abstract/22\">",
"      Hasegawa K, Tamari M, Shao C, et al. Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004; 115:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3967 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10854=[""].join("\n");
var outline_f10_38_10854=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLEMENT REGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Control of activation/initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Control of amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Control of membrane attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Control of anaphylatoxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLEMENT RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complement receptor 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complement receptor 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complement receptor 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complement receptor 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Receptors for C5a and C3a",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - C5a receptor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - C3a receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3967|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/56/2950\" title=\"figure 1\">",
"      Function of C1 inhibitor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3967|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/25/33180\" title=\"table 1\">",
"      Complement regulatory proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31675\" title=\"table 2\">",
"      Complement receptors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21321?source=related_link\">",
"      Agammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10855="Endomyocardial biopsy specimen with microvascular changes";
var content_f10_38_10855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Endomyocardial biopsy specimen with microvascular changes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Micrograph from routine endomyocardial biopsy after heart transplantation showing stenotic microvasculopathy as evidenced by prominent endothelial cells, thickening of the basal membranes, and neointima resulting in luminal narrowing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. C. B. Andersen, Rigshospitalet, Denmark.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10855=[""].join("\n");
var outline_f10_38_10855=null;
var title_f10_38_10856="Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis";
var content_f10_38_10856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Jeff Donovan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10856/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21714513\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenetic alopecia is the most common type of hair loss in men, and affects approximately 50 percent of Caucasian men by age 50. The condition is characterized by the progressive loss of terminal hairs on the scalp in a characteristic distribution. The anterior scalp, mid scalp, temporal scalp, and vertex of the scalp are typical sites of involvement (",
"    <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef63010 graphicRef83805 \" href=\"UTD.htm?42/14/43242\">",
"     picture 1A-D",
"    </a>",
"    ). \"Male balding\" and \"male pattern hair loss\" are additional terms used to refer to this condition.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, and diagnosis of androgenetic alopecia in men will be reviewed here. Other causes of nonscarring alopecia and the treatment of androgenetic alopecia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link\">",
"     \"Nonscarring hair loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link\">",
"     \"Treatment of androgenetic alopecia in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714520\">",
"    <span class=\"h1\">",
"     HAIR GROWTH CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to understand the pathophysiologic changes that occur during the progressive course of androgenetic alopecia, basic knowledge of the normal hair growth cycle is necessary. In humans, all terminal hair follicles are present at birth, and follicular growth occurs in cyclical manner. The growth cycle for follicles on the scalp consists of three main phases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The growth phase, termed",
"      <strong>",
"       anagen",
"      </strong>",
"      , lasts two to six years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/1\">",
"       1",
"      </a>",
"      ]. The duration of this phase determines the hair length.",
"     </li>",
"     <li>",
"      The involutional phase, termed",
"      <strong>",
"       catagen",
"      </strong>",
"      , lasts two to three weeks.",
"     </li>",
"     <li>",
"      The resting phase, termed",
"      <strong>",
"       telogen",
"      </strong>",
"      , lasts two to three months. Hair is released from the hair shaft and shed at the end of telogen, and the next hair cycle is initiated. Telogen hairs are characterized by a mature root sheath, or \"club,\" at the proximal end (",
"      <a class=\"graphic graphic_figure graphicRef50528 \" href=\"UTD.htm?2/12/2255\">",
"       figure 1",
"      </a>",
"      ). The term",
"      <strong>",
"       exogen",
"      </strong>",
"      has been used to describe the phase of active shedding [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the normal scalp, approximately 80 to 90 percent of follicles are growing (anagen), about 5 to 10 percent are resting (telogen), and 1 to 3 percent are undergoing involution (catagen) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Each day, up to 100 hairs are shed from the scalp and about the same number of follicles enter anagen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714527\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of male androgenetic alopecia varies by age and race. Approximately 30 percent of Caucasian men will develop androgenetic alopecia by age 30, 50 percent by age 50, and 80 percent by age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/6\">",
"     6",
"    </a>",
"    ]. Signs of androgenetic alopecia may first appear during adolescence. In one study, 16 percent of 15 to 17-year-old males had clinical evidence of androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/7\">",
"     7",
"    </a>",
"    ]. About 15 percent of men never develop androgenetic alopecia apart from the normal post-pubertal temporal recession that develops in nearly all men.",
"   </p>",
"   <p>",
"    Androgenetic alopecia is less common in Asian and African-American men than Caucasians and also starts later in life in these populations. Estimates suggest that African-American men are four times less likely to develop androgenetic alopecia than Caucasian men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family history of androgenetic alopecia is often present in balding men, but a negative history does not exclude the diagnosis. Men with a greater number of family members affected by male androgenetic alopecia are at an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/10\">",
"     10",
"    </a>",
"    ]. In particular, studies have found a high concordance of balding between fathers and sons [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. For example, a study of 572 men evaluated in a dermatology clinic for concerns unrelated to androgenetic alopecia found that young men with a balding father were more than five times more likely to have androgenetic alopecia than young men with fathers without the condition (relative risk 5.5, 95% CI 1.26-23.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714534\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name suggests, the pathogenesis of male androgenetic alopecia involves both hormonal (androgens) and genetic factors. Balding is considered an androgen-dependent trait that requires a genetic predisposition.",
"   </p>",
"   <p>",
"    The perception of hair \"loss\" in androgenetic alopecia results from a genetically determined and hormonally influenced shortening of the anagen phase, rather than the complete cessation of hair growth in affected areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/6\">",
"     6",
"    </a>",
"    ]. This shift in the hair cycle results in a reduction of the anagen:telogen ratio of hair follicles from a normal ratio of 12:1 in a non-balding scalp to less than 5:1 in sites of androgenetic alopecia. The shortened anagen phase leads to the production of shorter, thinner hair shafts, a process often called",
"    <strong>",
"     follicular miniaturization",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef83781 \" href=\"UTD.htm?41/0/41987\">",
"     picture 2",
"    </a>",
"    ). As additional follicles undergo miniaturization, hair coverage of the scalp progressively decreases. Eventually, the anagen phase may become so short that hair produced by a follicle fails to reach the skin surface. [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714541\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of androgens in the pathogenesis of male androgenetic alopecia is well established. Androgenetic alopecia develops after puberty, a phase associated with a dramatic increase in androgen production. Moreover, early studies showed that males castrated before puberty did not develop androgenetic alopecia unless they were treated with testosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cellular effects of androgens are mediated through the androgen receptor. Consistent with an important role of androgens in androgenetic alopecia, patients with androgen insensitivity syndrome, which is caused by a mutation in the androgen receptor, do not develop the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\", section on 'Complete androgen insensitivity (CAIS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dihydrotestosterone (DHT) is the key androgen involved in the induction and promotion of male androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/15\">",
"     15",
"    </a>",
"    ]. DHT is a potent metabolite of testosterone, and compared to testosterone, DHT has a several-fold greater affinity for the androgen receptor. The conversion of testosterone to DHT is mediated by the enzyme 5-alpha-reductase. The 5-alpha-reductase enzyme exists in two isoforms in scalp hair follicles &ndash; type 1 and type 2. The type I isoform of 5-alpha-reductase is located in sebaceous glands, epidermal and follicular keratinocytes, dermal papillae cells, and sweat glands. The type 2 isoform is located in the outer root sheath of hair follicles as well as the epididymis, vas deferens, seminal vesicles, and prostate. Although both isoforms have a role in androgenetic alopecia, the role of the type 2 isoform is greater. The importance of 5-alpha-reductase is evidenced by the absence of androgenetic alopecia in men with mutations in the 5-alpha-reductase type 2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/16\">",
"     16",
"    </a>",
"    ] as well as the beneficial effects of inhibitors of 5-alpha-reductase (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    ) on androgenetic alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=see_link\">",
"     \"Steroid 5-alpha-reductase 2 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Follicular miniaturization is caused by a hormonally-mediated process that occurs at the level of the hair follicle dermal papilla [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/17\">",
"     17",
"    </a>",
"    ]. At the cellular level, DHT binds to the androgen receptor, and the hormone-receptor complex then activates the genes responsible for the gradual transformation of large, terminal follicles to smaller follicles with a shortened anagen phase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The transforming growth factor-beta gene may be one of the genes involved in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrinsic differences in hormone metabolism and hormone receptors may contribute to the development of male androgenetic alopecia. Young men with androgenetic alopecia have higher levels of cellular 5-alpha-reductase and a higher quantity of androgen receptors in the balding scalp than in the non-balding scalp [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, production rates of DHT are higher in men with androgenetic alopecia than in men without the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/22\">",
"     22",
"    </a>",
"    ]. Although plasma testosterone concentrations are similar in balding and non-balding men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/23\">",
"     23",
"    </a>",
"    ], elevated levels of unbound testosterone (the active fraction of testosterone) have been detected in some men with androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714548\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetics play an important role in male androgenetic alopecia. In one study of approximately 500 monozygotic male twins and 400 dizygotic male twins between the ages of 25 and 36, 80 percent of the variance in the extent of hair loss was attributed to genetic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/26\">",
"     26",
"    </a>",
"    ]. Both maternal and paternal genetics appear to be involved and the mode of inheritance is best viewed as polygenic with variable penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/10,27\">",
"     10,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous studies have identified genetic susceptibility loci for androgenetic alopecia including the androgen receptor",
"    <span class=\"nowrap\">",
"     (AR)/EDAR2",
"    </span>",
"    locus on the X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/28\">",
"     28",
"    </a>",
"    ] , the",
"    <span class=\"nowrap\">",
"     PAX1/FOXA2",
"    </span>",
"    locus on chromosome 20p11 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and HDAC9 gene on chromosome 7p21.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/31\">",
"     31",
"    </a>",
"    ]. Chromosome 3q26 may also have a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/32\">",
"     32",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714555\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenetic alopecia is characterized by varying degrees of hair thinning and nonscarring terminal hair loss that typically begins in the temporal scalp, midfrontal scalp, or vertex area of the scalp (",
"    <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef63010 graphicRef83805 \" href=\"UTD.htm?42/14/43242\">",
"     picture 1A-D",
"    </a>",
"    ). The severity of involvement of these three areas is highly variable; some men bald more at the vertex and other men exhibit the most severe hair loss anteriorly. It is important to note that the vast majority (96 percent) of Caucasian men develop a minor amount of recession of the frontal hairline and temples after puberty (less than 2 cm) that does not correlate with the future development of androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/13\">",
"     13",
"    </a>",
"    ]. The midoccipital scalp is not usually affected in men, which allows for the transplantation of occipital hairs to other areas of the scalp during surgical hair restoration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=see_link&amp;anchor=H335327#H335327\">",
"     \"Treatment of androgenetic alopecia in men\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Hamilton-Norwood scale provides a helpful guide to classify male pattern hair loss (",
"    <a class=\"graphic graphic_figure graphicRef86709 \" href=\"UTD.htm?38/42/39591\">",
"     figure 2",
"    </a>",
"    ). The scale divides the clinical findings into seven stages and offers a visual depiction of the sequential stages of balding. However, not all men with androgenetic alopecia follow the hair loss patterns outlined by the Hamilton-Norwood scale. For example, 10 percent of men have a pattern that resembles female androgenetic alopecia (preservation of the frontal hairline and terminal hair loss in the central scalp) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Androgenetic alopecia is a continuous process that slowly progresses over the course of many years. It occurs in waves of activity, with some men noticing more rapid intervals of hair loss at certain times of their lives followed by periods of minimal activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714562\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of androgenetic alopecia in males is usually straightforward and can be made by obtaining a history from the patient and performing an examination of the patient&rsquo;s hair and scalp. A history of slowly progressive, patterned hair loss with evidence of follicular miniaturization and a negative hair pull test on examination is highly suggestive of androgenetic alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonscarring hair loss\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714569\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular miniaturization is one of the earliest signs of androgenetic alopecia (",
"    <a class=\"graphic graphic_picture graphicRef83781 \" href=\"UTD.htm?41/0/41987\">",
"     picture 2",
"    </a>",
"    ). The presence of miniaturized hairs can be seen either by examining the caliber of hair fibers against a color contrasting background or by using a handheld microscope or dermatoscope. Dermoscopy can reveal early variations in hair follicle diameter long before hair loss becomes clinically visible. The miniaturized hairs can be of various lengths and diameters since the effects on individual follicles are independent. The presence of uneven hair lengths and texture is consistent with androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family history of similar hair loss is often present in men with androgenetic alopecia (see",
"    <a class=\"local\" href=\"#H21714527\">",
"     'Epidemiology'",
"    </a>",
"    above). Rapid hair loss or hair loss accompanied by itching, burning, or scalp tenderness requires further evaluation since these features are not associated with androgenetic alopecia.",
"   </p>",
"   <p>",
"    Dermoscopy of the scalp (also known as trichoscopy) may be useful for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/34\">",
"     34",
"    </a>",
"    ]. Dermoscopic features of male androgenetic alopecia include hair diameter diversity, perifollicular",
"    <span class=\"nowrap\">",
"     pigmentation/peripilar",
"    </span>",
"    signs, and yellow dots [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/34\">",
"     34",
"    </a>",
"    ]. Focal atrichia may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714576\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination is not usually necessary for the diagnosis of male androgenetic alopecia. However, since androgenetic alopecia has distinctive histological features [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], biopsies can be used to confirm the diagnosis in the infrequent cases in which the diagnosis is uncertain.",
"   </p>",
"   <p>",
"    A 4 mm punch biopsy is the preferred procedure for obtaining a tissue specimen for diagnosis. We usually obtain two biopsies, one for horizontal (transverse) sectioning and one for vertical sectioning. Horizontal sectioning of the tissue specimen allows for visualization of more follicles and tends to yield more useful results than vertical sectioning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/36\">",
"     36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Horizontal sections",
"      </strong>",
"      &ndash; The histological features of androgenetic alopecia are more readily seen in horizontal sections. Depending on the severity of the clinical findings, these show a variable mixture of terminal, vellus, and vellus-like hair follicles in the dermis. The vellus and vellus-like hairs are less than 0.03 mm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/37\">",
"       37",
"      </a>",
"      ]. Terminal hairs (greater than 0.06 mm) are seen in the reticular dermis.",
"      <br/>",
"      <br/>",
"      The ratios of anagen to telogen (A:T) hair follicles and terminal to vellus (T:V) hair follicles are altered in androgenetic alopecia and can be readily evaluated with horizontal sections. In the course of androgenetic alopecia, the A:T ratio is reduced from 12:1 to less than 5:1. The T:V ratio is reduced from 7:1 to less than 2.5:1 in more advanced cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/38\">",
"       38",
"      </a>",
"      ]. These alterations in the T:V ratio can be extremely helpful in the diagnosis of androgenetic alopecia.",
"     </li>",
"     <li>",
"      <strong>",
"       Vertical sections",
"      </strong>",
"      &ndash; Vertical sections show terminal hair follicles rooted in the subcutaneous and reticular dermis and vellus hair follicles located more superficially in the papillary dermis. Vertical columns of connective tissue, known as follicular stelae or follicular streamers can be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/36,39\">",
"       36,39",
"      </a>",
"      ]. In androgenetic alopecia, the follicular stelae that originate in the deep dermis and underlie vellus hairs in the more superficial dermis may represent connective tissue that previously surrounded terminal hair follicles prior to miniaturization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inflammation is not uncommon in histologic specimens from androgenetic alopecia despite the fact it is classified as a noninflammatory form of hair loss. Mild perifollicular lymphohistiocytic inflammation is present in one-third of biopsies and moderate inflammation is present in approximately 40 percent of specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/36\">",
"     36",
"    </a>",
"    ]. This inflammation differs significantly from the intense peribulbar inflammation that is typically found in alopecia areata. Mild, perifollicular fibrosis is an additional feature that may be detected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/36\">",
"     36",
"    </a>",
"    ]. This fibrosis differs from the extensive scarring with obliteration of hair follicles seen in cicatricial alopecias.",
"   </p>",
"   <p>",
"    The presence of inflammation or fibrosis may have prognostic significance in androgenetic alopecia. In a study of male patients with androgenetic alopecia treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    , 55 percent of 22 men with inflammation or fibrosis responded to minoxidil compared with 77 percent of 22 men without histopathologic evidence for inflammation or fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/36\">",
"     36",
"    </a>",
"    ]. Further studies are necessary to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714583\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common hair disorders in the differential diagnosis of androgenetic alopecia are diffuse alopecia areata and telogen effluvium. It is important to remember that androgenetic alopecia may coexist with these conditions, further adding to the challenge of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714590\">",
"    <span class=\"h3\">",
"     Diffuse alopecia areata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alopecia areata is usually more acute in onset than androgenetic alopecia, typically does not follow a patterned distribution, and may be associated with hair loss on other body sites. Nail pitting may occur in alopecia areata, but is not a feature of androgenetic alopecia. Miniaturized hairs can be seen in both alopecia areata and androgenetic alopecia. A punch biopsy is helpful in difficult cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alopecia areata\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714597\">",
"    <span class=\"h3\">",
"     Telogen effluvium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the patterned hair loss of androgenetic alopecia, telogen effluvium generally leads to hair loss over the entire scalp, resulting in reduced hair volume. Telogen effluvium is usually associated with an acute event and the results of the hair pull test are positive. A history of a precipitating event or drug is helpful. A biopsy may assist with distinguishing androgenetic alopecia from telogen effluvium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonscarring hair loss\", section on 'Telogen effluvium'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21714576\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714604\">",
"    <span class=\"h1\">",
"     COMORBID DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714612\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the relationship between androgenetic alopecia and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. These studies identified elevated rates of cardiovascular disease in patients with vertex hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], vertex and frontal hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/45\">",
"     45",
"    </a>",
"    ], early onset hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/46\">",
"     46",
"    </a>",
"    ], and rapidly progressive hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of metabolic syndrome, a known risk factor for cardiovascular disease, was investigated in a case-control study of 40 men and 37 women with early-onset androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/44\">",
"     44",
"    </a>",
"    ]. The study found that subjects with androgenetic alopecia had a greater risk for metabolic syndrome (OR for men 10.5, 95% CI 3.3-32.5). Atheromatous plaques in the carotid arteries were also more likely to be found in patients with androgenetic alopecia (OR for men 5.93, 95% CI 1.5-22.9).",
"   </p>",
"   <p>",
"    There are no distinct guidelines for the early detection or prevention of cardiovascular disease in individuals with early onset androgenetic alopecia; however, clinicians should be cognizant of a potentially increased risk for cardiovascular disease in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714619\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between male pattern hair loss and prostate cancer has been reported. However, the strength of the association, if any, remains to be clarified. Some studies have reported a 1.5 to 2-fold increase in risk for prostate cancer in men with early onset androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], whereas other studies have found no association [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/24,50\">",
"     24,50",
"    </a>",
"    ] or an inverse relationship between the conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10856/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational materials on this topic are available for patients (see",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"     \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"    </a>",
"    ). We encourage you to print or e-mail this topic review, or to refer patients to our public web site,",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    , which includes this and other topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21714633\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androgenetic alopecia is a common condition in postpubertal males that is characterized by the loss of terminal hairs in select areas on the scalp. The prevalence of male androgenetic alopecia varies among ethnicities. (See",
"      <a class=\"local\" href=\"#H21714527\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both hormonal and genetic factors contribute to the development of male androgenetic alopecia. The effects of dihydrotestosterone on susceptible follicles leads to follicular miniaturization, which manifests clinically as the replacement of terminal hairs by short, thin (vellus) hairs. (See",
"      <a class=\"local\" href=\"#H21714534\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inheritance of male androgenetic alopecia is complex and likely involves both paternal and maternal factors. The mode of inheritance is best described as polygenic with variable penetrance. (See",
"      <a class=\"local\" href=\"#H21714548\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appearance of male androgenetic alopecia varies among individuals. The temporal, anterior, mid scalp,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertex areas of the scalp are typically affected (",
"      <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef63010 graphicRef83805 \" href=\"UTD.htm?42/14/43242\">",
"       picture 1A-D",
"      </a>",
"      ). The occipital scalp is usually spared. The loss of terminal hairs slowly progresses over the course of years. (See",
"      <a class=\"local\" href=\"#H21714555\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of androgenetic alopecia is usually made clinically. For the infrequent cases in which the diagnosis is uncertain, a biopsy can be used to confirm the diagnosis. Horizontal sectioning of the biopsy specimen is preferred. (See",
"      <a class=\"local\" href=\"#H21714562\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An association between androgenetic alopecia and cardiovascular disease has been reported. Although there are no specific guidelines for the detection or prevention of cardiovascular disease in men with androgenetic alopecia, clinicians should remain cognizant of the possibility of an increased risk in this population. (See",
"      <a class=\"local\" href=\"#H21714604\">",
"       'Comorbid disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/1\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/2\">",
"      Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/3\">",
"      Higgins CA, Westgate GE, Jahoda CA. From telogen to exogen: mechanisms underlying formation and subsequent loss of the hair club fiber. J Invest Dermatol 2009; 129:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/4\">",
"      Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol 1993; 129:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/5\">",
"      Whiting DA. Chronic telogen effluvium. Dermatol Clin 1996; 14:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/6\">",
"      Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     Trancik RJ, Spindler JR, Rose S, et al. Incidence of androgenetic alopecia in males 15 to 17 years of age. Poster presented at: 3rd Intercontinental Meeting of the Hair Research Societies June 13-15, 2001, Tokyo. p.127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/8\">",
"      Setty LR. Hair patterns of scalp of white and Negro males. Am J Phys Anthropol 1970; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/9\">",
"      Paik JH, Yoon JB, Sim WY, et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001; 145:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/10\">",
"      K&uuml;ster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984; 11:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/11\">",
"      Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 1998; 110:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/12\">",
"      Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol 2001; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/13\">",
"      HAMILTON JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951; 53:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/14\">",
"      Patterson MN, McPhaul MJ, Hughes IA. Androgen insensitivity syndrome. Baillieres Clin Endocrinol Metab 1994; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/15\">",
"      Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol 2002; 198:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/16\">",
"      Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/17\">",
"      Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol 2006; 154:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/18\">",
"      Sawaya ME. Purification of androgen receptors in human sebocytes and hair. J Invest Dermatol 1992; 98:92S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/19\">",
"      Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/20\">",
"      Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/21\">",
"      Sawaya ME. Steroid chemistry and hormone controls during the hair follicle cycle. Ann N Y Acad Sci 1991; 642:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/22\">",
"      Vierhapper H, Nowotny P, Maier H, Waldh&auml;usl W. Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 2001; 86:5762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/23\">",
"      Schmidt JB, Lindmaier A, Spona J. Hormonal parameters in androgenetic hair loss in the male. Dermatologica 1991; 182:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/24\">",
"      Demark-Wahnefried W, Lesko SM, Conaway MR, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/25\">",
"      Cipriani R, Ruzza G, Foresta C, et al. Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia. Br J Dermatol 1983; 109:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/26\">",
"      Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol 2003; 121:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/27\">",
"      Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995; 98:95S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/28\">",
"      Hillmer AM, Hanneken S, Ritzmann S, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/29\">",
"      Hillmer AM, Brockschmidt FF, Hanneken S, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008; 40:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/30\">",
"      Richards JB, Yuan X, Geller F, et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/31\">",
"      Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol 2011; 165:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/32\">",
"      Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet 2008; 82:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/33\">",
"      Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/34\">",
"      Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol 2011; 38:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/35\">",
"      Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001; 45:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/36\">",
"      Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28:755.",
"     </a>",
"    </li>",
"    <li>",
"     Whiting DA, Reisenauer AK, Parker D, et al.. Disorders of cutaneous appendages. In: Dermatopathology, 3rd ed, Barnhill RL, Crowson AN, Magro CM, et al..  (Eds), McGraw-Hill, 2010. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/38\">",
"      Horenstein MG, Jacob JS. Follicular streamers (stelae) in scarring and non-scarring alopecia. J Cutan Pathol 2008; 35:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/39\">",
"      Headington JT. Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle. Arch Dermatol 1984; 120:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/40\">",
"      Cotton SG, Nixon JM, Carpenter RG, Evans DW. Factors discriminating men with coronary heart disease from healthy controls. Br Heart J 1972; 34:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/41\">",
"      Hirsso P, Rajala U, Hiltunen L, et al. Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology 2007; 214:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/42\">",
"      Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. JAMA 1993; 269:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/43\">",
"      Lotufo PA, Chae CU, Ajani UA, et al. Male pattern baldness and coronary heart disease: the Physicians' Health Study. Arch Intern Med 2000; 160:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/44\">",
"      Arias-Santiago S, Guti&eacute;rrez-Salmer&oacute;n MT, Castellote-Caballero L, et al. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 2010; 63:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/45\">",
"      Schnohr P, Lange P, Nyboe J, et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J 1995; 130:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/46\">",
"      Herrera CR, D'Agostino RB, Gerstman BB, et al. Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995; 142:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/47\">",
"      Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2000; 9:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/48\">",
"      Yassa M, Saliou M, De Rycke Y, et al. Male pattern baldness and the risk of prostate cancer. Ann Oncol 2011; 22:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/49\">",
"      Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/50\">",
"      Hsieh CC, Thanos A, Mitropoulos D, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/51\">",
"      Cremers RG, Aben KK, Vermeulen SH, et al. Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer 2010; 46:3294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10856/abstract/52\">",
"      Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol 2010; 34:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83783 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-A3347AB727-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10856=[""].join("\n");
var outline_f10_38_10856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21714633\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714513\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714520\">",
"      HAIR GROWTH CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714527\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714534\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714541\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714548\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714555\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714562\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714569\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714576\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714583\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21714590\">",
"      - Diffuse alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21714597\">",
"      - Telogen effluvium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714604\">",
"      COMORBID DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714612\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21714619\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21714633\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/83783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/83783|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2255\" title=\"figure 1\">",
"      Telogen and anagen hairs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/42/39591\" title=\"figure 2\">",
"      Hamilton-Norwood scale for male androgenetic alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/83783|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/50/6950\" title=\"picture 1A\">",
"      Androgenetic alopecia bitemporal recession",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/52/31559\" title=\"picture 1B\">",
"      Androgenetic alopecia vertex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29253\" title=\"picture 1C\">",
"      Androgenetic alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40692\" title=\"picture 1D\">",
"      Androgenetic alopecia extensive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/0/41987\" title=\"picture 2\">",
"      Follicular miniaturization in androgenetic alopecia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=related_link\">",
"      Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=related_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23336?source=related_link\">",
"      Treatment of androgenetic alopecia in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10857="Erythrocytosis following renal transplantation";
var content_f10_38_10857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythrocytosis following renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Demetrios V Vlahakos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10857/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttransplant erythrocytosis (PTE) occurs in 8 to 15 percent of renal transplant recipients and usually affects patients with well-preserved graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The pathogenesis and treatment of this disorder is reviewed here. An overview of the general approach to the patient with polycythemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTE is defined as persistently elevated hemoglobin and hematocrit levels that occur following renal transplantation and persist for more than six months in the absence of thrombocytosis, leukocytosis or another potential cause of erythrocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The threshold hematocrit used to define PTE is variable and ranges between 51 to 54 percent: most clinicians use 51 percent (corresponding to a hemoglobin concentration of approximately 17",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,6-14\">",
"     2,6-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTE occurs in 8 to 15 percent of renal transplant recipients; a few studies have reported incidences as high as 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1-5,15\">",
"     1-5,15",
"    </a>",
"    ]. The disparity in reported prevalence is due in part to the variably defined hematocrit thresholds used and the inclusion of transitory erythrocytosis (ie, persisting for less than six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"     2",
"    </a>",
"    ]. Differences in immunosuppressive regimens may also contribute to disparities between centers in the reported prevalence of PTE since individual agents have variable effects on hemoglobin.",
"   </p>",
"   <p>",
"    The incidence of PTE appears to be decreasing. Erythrocytosis defined as hemoglobin &gt;17",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    was reported in 19 percent of those transplanted between 1993 to 1996, but only 8 percent of those transplanted between 1997 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719588705\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential risk factors associated with PTE include male gender, a rejection-free course and preserved GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Smoking history and diabetes have been shown to increase the risk of PTE in some [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/6,16\">",
"     6,16",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/4,5,17\">",
"     4,5,17",
"    </a>",
"    ]. Almost all cases of PTE develop in transplant recipients who have retained native kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/5,18-21\">",
"     5,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Male gender has emerged as a risk factor in multiple studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 101 patients with PTE included 82 men and only 18 women [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 511 recipients, male gender was independently associated with PTE (HR 3.72, 95% CI 1.54-1.90) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of renal transplantation through the mid 1990s, men comprised 61 percent of the renal graft recipients, but 84 percent of PTE patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The original cause of end-stage renal disease also affects the risk of PTE. Patients with polycystic kidney disease and glomerulonephritis were more likely to develop PTE in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/17\">",
"     17",
"    </a>",
"    ]. Renal artery stenosis of the native or transplanted kidney was suggested as a risk factor for PTE in early case reports, but this has not been confirmed in subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,6,22,23\">",
"     2,6,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTE may be more common among recipients of simultaneous pancreas kidney transplantation. This was suggested by a retrospective analysis of 94 simultaneous pancreas and kidney transplant recipients, 174 living related donor recipients and 53 type 1 diabetic kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients who received a simultaneous pancreas kidney transplant had a higher incidence of PTE compared with living related renal transplant recipients (16 versus 3 percent, respectively). There were no instances of PTE among the 53 diabetic kidney transplant recipients.",
"   </p>",
"   <p>",
"    Risk factors for non-transplant-associated erythrocytosis, such as renal cell cancer, breast cancer, hepatocellular carcinoma, chronic obstructive pulmonary disease (COPD), cerebellar hemangiomas, uterine myomata, and pheochromocytoma are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnostic approach to the patient with polycythemia\", section on 'Evaluation of secondary erythrocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PTE is multifactorial and not well understood. Some patients appear to be particularly susceptible to PTE, suggesting that patient-specific risk factors play a role. As an example, in one report of a patient who underwent two transplants, PTE occurred after both surgeries despite the presence of severe anemia in the intervening twelve months between transplantation of the first and second graft [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following hormonal systems and growth factors have been implicated in the pathogenesis of PTE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythropoietin",
"     </li>",
"     <li>",
"      Hematopoietic growth factors such as insulin-like growth factor-1 and its binding proteins and serum-soluble stem cell factor (sSCF)",
"     </li>",
"     <li>",
"      Renin-angiotensin system (RAS)",
"     </li>",
"     <li>",
"      Endogenous androgens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased erythropoietin has been shown in many [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/18,25,26\">",
"     18,25,26",
"    </a>",
"    ] though not all [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1,7,26\">",
"     1,7,26",
"    </a>",
"    ] studies. As an example, in one study, serum erythropoietin concentrations were elevated in six of seven patients with PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even among PTE patients with serum erythropoietin concentrations within normal range, the concentration may be inappropriately elevated for a given hemoglobin. In one study, the mean",
"    <span class=\"nowrap\">",
"     observed/expected",
"    </span>",
"    serum erythropoietin ratio was elevated among 13 PTE patients compared with that of 42 renal transplant recipients without erythrocytosis (8.6 versus 0.3, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The demonstration of increased or even normal erythropoietin levels suggests that PTE may be a form of &ldquo;tertiary hypererythropoietinemia&rdquo; in which mechanisms that suppress erythropoietin synthesis or secretion and are normally provoked by a normal or elevated hematocrit do not function adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,18\">",
"     2,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The source of excess erythropoietin appears to be the native kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. This was suggested by one detailed study of three patients that demonstrated higher blood erythropoietin titers obtained by selective catheterization from the renal veins of native kidneys versus transplanted kidneys (41 versus 13",
"    <span class=\"nowrap\">",
"     mU/mL,",
"    </span>",
"    respectively). In one patient, erythropoietin titers and hematocrit were decreased within two weeks of bilateral native nephrectomy.",
"   </p>",
"   <p>",
"    With the exception of phlebotomy, therapies that correct PTE are generally accompanied by a reduction in erythropoietin levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    normalization of the erythropoietin versus hematocrit relationship. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Treatment overview'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hematopoietic factors, including insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding proteins and the serum-soluble stem cell factor (sSCF), may either enhance the sensitivity to erythropoietin or directly promote erythropoiesis in patients with PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1,27-29\">",
"     1,27-29",
"    </a>",
"    ]. In one study, cultured erythroid progenitors from patients with PTE were shown to have increased sensitivity to erythropoietin",
"    <em>",
"     in vitro",
"    </em>",
"    compared with erythroid progenitors from transplant recipients with normal hematocrits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased concentrations of plasma IGF-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its major binding proteins have been demonstrated in patients with PTE compared with transplant recipients with normal hematocrits. In one series of 40 PTE patients, treatment with an angiotensin converting enzyme (ACE) inhibitor reduced concentrations of both EPO and IGF-1 from 15.4&plusmn;6.2 to 11.2&plusmn;6.8",
"    <span class=\"nowrap\">",
"     mU/ml,",
"    </span>",
"    and from 364&plusmn;99 to 280&plusmn;129",
"    <span class=\"nowrap\">",
"     ng/ml,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms underlying increased IGF-I concentrations are unknown.",
"   </p>",
"   <p>",
"    Serum-soluble stem cell factor (sSCF), which stimulates the growth of erythroid progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/29\">",
"     29",
"    </a>",
"    ] has been shown to correlate with both hematocrit values and with the",
"    <span class=\"nowrap\">",
"     observed/expected",
"    </span>",
"    erythropoietin values in PTE patients, suggesting a possible role in pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of the renin-angiotensin system (RAS) appears to stimulate erythropoiesis and may contribute to PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/31\">",
"     31",
"    </a>",
"    ]. Angiotensin II stimulates growth of erythroid progenitors and augments erythropoietin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In this regard, activation of the angiotensin II receptor in PTE patients may enhance erythropoietin production in the graft or the native kidneys, and directly activate red cell precursors in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/8,32,34-40\">",
"     8,32,34-40",
"    </a>",
"    ]. In addition, angiotensin II induces hypoxia-inducible factor, a transcription factor that promotes the production of erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical data indirectly support the role of the RAS system in erythropoiesis. As an example, erythrocytosis has been reported in patients with renin-secreting juxtaglomerular cell tumors and in patients with Bartter syndrome, a condition characterized by hyperreninemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. By contrast, RAS inactivation by angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) inhibits erythropoiesis in most patients, although it does not cause clinically significant anemia in the vast majority [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have shown that ACE inhibitors and ARBs may inhibit erythropoiesis in renal transplant recipients and non-transplant cohorts. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      was associated with anemia in renal transplant recipients with high-normal hematocrit at baseline, but not in those with lower baseline hematocrits [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Cochrane meta-analysis that included 332 renal transplant recipients, ACE inhibitors compared with calcium channel blockers were associated with a 12.96-point lower hemoglobin concentration (95% CI 15.7-10.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      decreased hematocrits in nontransplanted individuals who have secondary polycythemia due to high-altitude or chronic obstructive pulmonary disease (COPD) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      decreased hemoglobin levels without affecting plasma volume and increased the odds for anemia by approximately 50 percent in cardiac patients with low ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACE inhibitors or ARBs may increase erythropoietin requirements in patients treated with maintenance dialysis, whereas their withdrawal allows decreases in erythropoietin doses [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms by which ACE inhibitors and ARBs inhibit erythropoiesis are incompletely defined and some effects may not be common to both classes of drugs. As an example, ACE inhibitors but not ARBs cause an increase in the protein, Ac-SDKP (goralatide) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/35-37,52\">",
"     35-37,52",
"    </a>",
"    ]. Goralatide inhibits pluripotent stem cell entry into S phase and is usually metabolized by angiotensin converting enzyme thereby diminishing erythropoiesis. However, this mechanism does not explain the effectiveness of ARBs in correcting PTE, suggesting that other mechanisms are also operative.",
"   </p>",
"   <p>",
"    Some studies have shown that, among PTE patients with normal or high erythropoietin concentrations, the ACE inhibitor-induced reduction in hematocrit is associated with a fall in plasma erythropoietin concentrations, suggesting an erythropoietin-dependent mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/7,53\">",
"     7,53",
"    </a>",
"    ]. However, ACE inhibitors are also effective among patients whose erythropoietin concentrations are initially suppressed or which do not fall significantly after therapy is begun, suggesting that these agents may also act via an erythropoietin-independent mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1,7,54\">",
"     1,7,54",
"    </a>",
"    ]. Also compatible with an erythropoietin-independent mechanism is the observation that withdrawal of the ACE inhibitor in patients with PTE results in a gradual rise in hematocrit without a concurrent elevation in erythropoietin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endogenous androgens may play a role in the development of PTE. Male gender is one of the most important risk factors for the development of PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"     2",
"    </a>",
"    ]. Androgens directly stimulate erythroid progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/56\">",
"     56",
"    </a>",
"    ] and indirectly promote erythropoiesis by stimulating either endogenous erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/57\">",
"     57",
"    </a>",
"    ] or the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719588281\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttransplantation erythrocytosis usually occurs 8 to 24 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/5\">",
"     5",
"    </a>",
"    ]. In the absence of treatment, PTE spontaneously remits in one fourth of patients within two years from onset. In the remainder of patients, PTE persists for a number of years after which it may remit in association with deteriorating renal function due to chronic rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/15,25\">",
"     15,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other forms of erythrocytosis, approximately 60 percent of patients with PTE experience malaise, headache, plethora, lethargy, and dizziness; 10 to 30 percent develop thromboembolic events; and 1 to 2 percent eventually die of associated complications if untreated and if erythrocytosis does not spontaneously remit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H3#H3\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Thrombotic events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thromboembolic events may involve both veins and arteries and are manifested as thrombosis of digital or branchial arteries, thrombophlebitis, stroke, or pulmonary embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/6,15,18,54\">",
"     6,15,18,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study from a single transplant center in which the incidence of PTE was 17 percent, the clinical characteristics of those with (53 patients) and without (49 control recipients) PTE were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/6\">",
"     6",
"    </a>",
"    ]. Approximately 10 percent of patients with erythrocytosis had at least one episode of phlebitis, complicated by a pulmonary embolus in one patient. Ten percent of patients had cerebrovascular events. By contrast, there were no thromboembolic events in the control population.",
"   </p>",
"   <p>",
"    Platelet and leukocyte counts are normal and arterial blood gases are normal in patients with PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PTE is made by the demonstration of a hemoglobin greater than 17",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematocrit greater than 51 percent that persists for over six months after transplantation and by the exclusion of common causes of nontransplant-associated erythrocytosis including malignancies and, in selected patients, chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic approach to the patient with polycythemia\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of PTE is different from that of erythrocytosis in a patient who has not received a transplant, since transplant patients receive a thorough evaluation prior to surgery, during which a baseline hemoglobin is established and longstanding pulmonary disease and congenital disorders are excluded. The evaluation focuses on acquired disorders that may contribute to erythrocytosis and for which the transplant population is at higher risk, including malignancies such as renal cell carcinoma, breast cancer.",
"   </p>",
"   <p>",
"    We generally obtain an ultrasound with Doppler waveform analysis of renal arteries of the native and transplanted kidney and assessment of cytology of three morning urine samples in order to exclude renal artery stenosis and an underlying renal carcinoma. If these studies are suspicious for renovascular hypertension or malignancy, further evaluation is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women we obtain a mammogram if one has not been obtained within one-year to exclude breast cancer.",
"   </p>",
"   <p>",
"    In patients with a history of hepatitis B or C virus infection who are at increased risk for hepatocellular carcinoma, we also obtain a liver ultrasound and alfa fetoprotein to screen for hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a smoking history exceeding 20 years or a clinical history of chronic obstructive pulmonary disease, a chest x-ray, pulmonary function tests and arterial blood gases may be obtained as hypoxemia and chronic obstructive pulmonary disease are common causes of non-transplant-associated erythrocytosis. However, as noted above, these tests have generally been performed prior to transplantation and the utility of repeating this evaluation is not clear since transplantation-associated erythrocytosis usually occurs within a few months following transplantation.",
"   </p>",
"   <p>",
"    We do not perform imaging studies to rule out other uncommon causes of erythrocytosis such as hemangioblastomas, pheochromocytoma or uterine myomata unless there is an additional indication besides the presence of erythrocytosis.",
"   </p>",
"   <p>",
"    By contrast with the general population with erythrocytosis, the measurement of erythropoietin concentrations is not helpful among transplant recipients since high and low concentrations have been demonstrated among PTE patients.",
"   </p>",
"   <p>",
"    Measurement of renin angiotensin system (RAS) activity, goralatide or IGF-1 concentrations are also not helpful in making the diagnosis or direct treatment and are not performed among transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred initial treatment for patients with PTE who have a hemoglobin concentration less than 18.5",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    is an ARB or ACE inhibitor, since these agents are effective in the majority of patients, are reasonably safe and, among many patients, provide a necessary antihypertensive effect.",
"   </p>",
"   <p>",
"    The choice between an ARB and an ACE inhibitor is dependent upon patient and physician preference; although limited data suggest that ACE inhibitors may be somewhat more effective in lowering the hemoglobin, they are more likely than ARBs to produce side effects.",
"   </p>",
"   <p>",
"    We initiate therapy with an ARB, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    at 50",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The dose may be increased to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or even higher if no response is observed within four weeks or the blood pressure remains elevated. If an adequate lowering of the hematocrit is not seen after an additional four weeks, losartan may be replaced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , administered at 10 to 40 mg daily, or an equivalent dosage of another ACE inhibitor.",
"   </p>",
"   <p>",
"    Patients who present with very high hemoglobins may be at risk for cerebrovascular events, although the exact hemoglobin concentration at which risk is increased is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H8323402#H8323402\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'The optimal hematocrit in PV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore we generally treat patients who present with hemoglobin concentration greater than 18.5",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    with phlebotomy along with the ARB or ACE inhibitor.",
"   </p>",
"   <p>",
"    Patients in whom an ARB or ACE inhibitor is ineffective in reducing the hemoglobin concentration are treated with serial phlebotomy. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    has been shown to be effective in treating PTE, it is rarely used except in selected patients because of the requirement for monitoring serum concentrations and because of undesirable side effects including tremor and insomnia. Similarly antiproliferative agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or MTOR inhibitors may decrease erythrocytosis but altering the immunosuppressive regimen to include such agents is not commonly done in the absence of other indications.",
"   </p>",
"   <p>",
"    Studies supporting individual therapies are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264990867\">",
"    <span class=\"h2\">",
"     ACE inhibitors and ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1,2,7,9,53,54,59-61\">",
"     1,2,7,9,53,54,59-61",
"    </a>",
"    ] and ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/19,61-63\">",
"     19,61-63",
"    </a>",
"    ] have been used to correct PTE. A 2007 systematic review of eight randomized trials including 231 transplant recipients showed that treatment with either an ACE inhibitor or ARB significantly lowered the hematocrit compared with control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dose-dependent decrease in hemoglobin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematocrit values is observed in more than 90 percent of PTE patients within two to six weeks of treatment with an ACE inhibitor or ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/1,2,7,9,10,19,53,54,59-61,65\">",
"     1,2,7,9,10,19,53,54,59-61,65",
"    </a>",
"    ]. The nadir hematocrit is usually reached within three to six months and the attained level remains stable with continued treatment during long-term observation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/9,11,60,66,67\">",
"     9,11,60,66,67",
"    </a>",
"    ]. If the ACE inhibitor or ARB is discontinued, the hematocrit values rise gradually over the next three months toward pretreatment levels in the majority of patients. However erythrocytosis does not recur in a substantial fraction of patients (20 to 30 percent) who discontinue treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/55,59\">",
"     55,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the choice between an ACE inhibitor and ARB depends on individual and physician and patient preference. Direct comparisons between ACE inhibitors and ARBs for the treatment of PTE are limited. One randomized trial compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 27 patients with PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/61\">",
"     61",
"    </a>",
"    ]. The response rate was similar with both drugs (75 to 80 percent), but enalapril produced a greater reduction in hemoglobin concentration in the responders (3.3 versus 1.7",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    Cessation of therapy led to return to baseline hemoglobin levels in 10 of 13 patients. There was a trend for a slower return to baseline after discontinuation of losartan (seven versus three months for enalapril). A high frequency of relapse has also been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ARBs are less commonly associated with side effects including cough and angioedema. Both ACE inhibitors and ARBs may cause renal dysfunction, postural hypotension, hyperkalemia, and erectile impotence. These side effects are dose-dependent and improve after dosage reduction (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Cough'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    As yet, severe adverse reactions, such as angioneurotic edema or anaphylactoid reactions, have not been reported in patients with PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/7,9,66\">",
"     7,9,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience, approximately 5 to 10 percent of patients will fail to respond to an ARB or ACE inhibitor: such patients are generally unresponsive to all other ACE inhibitors and ARBs. A few of those patients may respond to the combination of an ACE inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    . However, theophylline is generally not used except among patients who do not wish to undergo repeated phlebotomy. Phlebotomy is used if ARBs or ACE inhibitors fail to control PTE. (See",
"    <a class=\"local\" href=\"#H264991850\">",
"     'Phlebotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanisms underlying the ACE inhibitor-induced decrease in erythrocytes are unknown although one study has suggested that ACE inhibitors induce apoptosis of the erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, RAS inhibition may decrease erythropoietin production and restore the",
"    <span class=\"nowrap\">",
"     observed/expected",
"    </span>",
"    serum erythropoietin ratio towards normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264991850\">",
"    <span class=\"h2\">",
"     Phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebotomy is used for patients with PTE who do not respond to treatment with an ARB or ACE inhibitor. [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/68\">",
"     68",
"    </a>",
"    ]. As noted above, phlebotomy is also used in conjunction with ACE inhibitors or ARBs for patients who present with hemoglobin greater than 18.5",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Treatment overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although phlebotomy is quite effective in normalizing hematocrit levels and may be used chronically for PTE, it leads to severe iron deficiency in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is an effective treatment for PTE. Theophylline appears to act as an adenosine antagonist in this setting, suggesting that adenosine facilitates both the release and perhaps the bone marrow response to erythropoietin. In a prospective trial of eight patients with PTE and five normal controls, an eight week course of theophylline reduced the hematocrit from 58 to 46 percent in those with PTE, and from 43 to 39 percent in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/69\">",
"     69",
"    </a>",
"    ]. Another study found that theophylline can lower the hematocrit by as much as 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    , however, has a narrow therapeutic window and even at relatively small doses can cause side effects, such as headache, nervousness, and insomnia and adversely affect the patient&rsquo;s quality of life. In addition, theophylline is not as predictably effective as an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/39,59\">",
"     39,59",
"    </a>",
"    ]. As an example, one report of 28 patients with PTE compared theophylline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , and no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 10 patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      , the hematocrit decreased from 57 to 45 percent at two months.",
"     </li>",
"     <li>",
"      Among the nine patients administered 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      (given in two doses), the average hematocrit was reduced from 56 to 52 percent, but remained above 51 percent in five.",
"     </li>",
"     <li>",
"      Nine patients did not receive medical treatment for PTE. After three months, PTE persisted in eight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    showed no response of PTE to aminophylline [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For selected patients who cannot tolerate ACE inhibitors or ARBs, and who do not wish to undergo repeated phlebotomy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    may be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6423914\">",
"    <span class=\"h2\">",
"     Antiproliferative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altering the immunosuppressive regimen is generally not done to treat PTE in the absence of other indications, although antiproliferative agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    and MTOR inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    have been associated with anemia and may decrease the risk of PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/4,54\">",
"     4,54",
"    </a>",
"    ]. In one study, PTE occurred more frequently among graft recipients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A compared with azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/54\">",
"     54",
"    </a>",
"    ]. Another study of 214 kidney pancreas recipients found a lower incidence of PTE among patients treated with sirolimus compared to mycophenolate mofetil (7 versus 19 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altering the immunosuppressive regimen may be considered for patients who do not respond to ACE inhibitors or ARBs, do not wish to undergo repeated phlebotomy and do not wish to start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    due to perceived side effects, provided it is immunologically permissible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2063178\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ketanserin, a serotonin 5-HT2 receptor antagonist, has been tried in a small pilot study with promising results, but no further investigation has been carried out and ketanserin has not gained acceptance as a therapeutic modality in PTE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264991067\">",
"    <span class=\"h2\">",
"     Goals and duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal hemoglobin among patients with PTE is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H8323402#H8323402\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'The optimal hematocrit in PV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally target a hemoglobin level less than 17.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    We continue therapy for PTE indefinitely since relapse of erythrocytosis is common and since the majority of renal transplant recipients are hypertensive, and these drugs may slow the rate of progressive renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,19,61\">",
"     2,19,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapse of erythrocytosis is common if treatment is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10857/abstract/2,19,61\">",
"     2,19,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25596288\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posttransplant erythrocytosis (PTE) is defined as a hemoglobin concentration greater than 17",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematocrit greater than 51 percent that occurs following transplantation, persists for more than 6 months and occurs in the absence of another underlying cause. It is reported to occur in 8 to 15 percent of renal transplant recipients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTE most often occurs within the first 8 to 24 months after transplantation. Symptoms include malaise, headache, plethora, lethargy, and dizziness. Approximately 10 percent develop thromboembolic events that involve both veins and arteries and are manifested as thrombosis of digital or branchial arteries, thrombophlebitis, stroke, or pulmonary embolus. Relapse is common after treatment is discontinued. (See",
"      <a class=\"local\" href=\"#H719588281\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation includes the exclusion of renovascular hypertension or underlying malignancy and, in selected patients, an evaluation for chronic obstructive pulmonary disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred initial treatment for patients with PTE who have a hemoglobin concentration less than 18.5",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      is an ARB or ACE inhibitor, since these agents are effective in the majority of patients, are reasonably safe and, among many patients, provide a necessary antihypertensive effect. Phlebotomy is used if ACE inhibitors or ARBs are ineffective.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      may be effective in some patients who cannot take ACE inhibitors or ARBs and for whom repeated phlebotomy is unacceptable. Alteration of the immunosuppressive regimen to include antiproliferative agents may be effective in treating PTE but is rarely done in the absence of other indications. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For all patients with PTE and a hemoglobin concentration greater than 17 but less than 18.5",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      we recommend treatment with either an ACE inhibitor or ARB rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      or phlebotomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We generally use an ARB such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      at 50",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The dose may be increased to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if no response is observed within four weeks. Patients who do not respond to an ARB may respond to an ACE inhibitor such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      , although patients who do not respond to one ACE inhibitor are generally equally unresponsive to all other ACE inhibitors as well as other ARBs. (See",
"      <a class=\"local\" href=\"#H264990867\">",
"       'ACE inhibitors and ARBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with hemoglobin greater than 18.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      we recommend phlebotomy in addition to an ARB or ACE inhibitor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H264991850\">",
"       'Phlebotomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H22#H22\">",
"       \"Prognosis and treatment of polycythemia vera\", section on 'Treatment issues'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who do not respond to ARBs or ACE inhibitors, we suggest intermittent phlebotomy rather than other therapies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      or antiproliferative agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H264991850\">",
"       'Phlebotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H264991067\">",
"       'Goals and duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/1\">",
"      Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/2\">",
"      Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003; 63:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/3\">",
"      Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/4\">",
"      Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transplant 2009; 23:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/5\">",
"      Einollahi B, Lessan-Pezeshki M, Nafar M, et al. Erythrocytosis after renal transplantation: review of 101 cases. Transplant Proc 2005; 37:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/6\">",
"      Wickre CG, Norman DJ, Bennison A, et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983; 23:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/7\">",
"      Danovitch GM, Jamgotchian NJ, Eggena PH, et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/8\">",
"      Morrone LF, Di Paolo S, Logoluso F, et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/9\">",
"      Torregrosa JV, Campistol JM, Montesinos M, et al. Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up. Transplantation 1994; 58:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/10\">",
"      Conlon PJ, Farrell J, Donohoe J, Walshe JJ. The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 1993; 56:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/11\">",
"      Lal SM, Trivedi HS, Ross G Jr. Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients. Int J Artif Organs 1995; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/12\">",
"      Thevenod F, Radtke HW, Gr&uuml;tzmacher P, et al. Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia. Kidney Int 1983; 24:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/13\">",
"      Dagher FJ, Ramos E, Erslev A, et al. Erythrocytosis after renal allotransplantation: treatment by removal of the native kidneys. South Med J 1980; 73:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/14\">",
"      Hern&aacute;ndez E, Morales JM, Andr&eacute;s A, et al. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplant Proc 1995; 27:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/15\">",
"      Kessler M, Hestin D, Mayeux D, et al. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol 1996; 45:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/16\">",
"      Qunibi WY, Barri Y, Devol E, et al. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991; 40:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/17\">",
"      Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors of erythrocytosis post renal transplantation. Saudi J Kidney Dis Transpl 2008; 19:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/18\">",
"      Dagher FJ, Ramos E, Erslev AJ, et al. Are the native kidneys responsible for erythrocytosis in renal allorecipients? Transplantation 1979; 28:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/19\">",
"      Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/20\">",
"      Frei D, Guttmann RD, Gorman P. A matched-pair control study of postrenal transplant polycythemia. Am J Kidney Dis 1982; 2:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/21\">",
"      Gaston RS, Julian BA, Diethelm AG, Curtis JJ. Effects of enalapril on erythrocytosis after renal transplantation. Ann Intern Med 1991; 115:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/22\">",
"      Schramek A, Better OS, Adler O, et al. Hypertensive crisis, erythrocytosis, and uraemia due to renal-artery stenosis of kidney transplants. Lancet 1975; 1:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/23\">",
"      Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980; 140:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/24\">",
"      Guerra G, Indahyung R, Bucci CM, et al. Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation. Am J Transplant 2010; 10:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/25\">",
"      Aeberhard JM, Schneider PA, Vallotton MB, et al. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 1990; 50:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/26\">",
"      Ilan Y, Dranitzki-Elhallel M, Rubinger D, et al. Erythrocytosis after renal transplantation. The response to theophylline treatment. Transplantation 1994; 57:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/27\">",
"      Kiykim AA, Genctoy G, Horoz M, et al. Serum stem cell factor level in renal transplant recipients with posttransplant erythrocytosis. Artif Organs 2009; 33:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/28\">",
"      Brox AG, Mangel J, Hanley JA, et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 1998; 66:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/29\">",
"      Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992; 148:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/30\">",
"      Lamperi S, Carozzi S. Erythroid progenitor growth in erythrocytosic transplanted patients. Artif Organs 1985; 9:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/31\">",
"      Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010; 56:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/32\">",
"      Gossmann J, Burkhardt R, Harder S, et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 2001; 60:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/33\">",
"      Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/34\">",
"      Glicklich D, Kapoian T, Mian H, et al. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation 1999; 68:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/35\">",
"      Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/36\">",
"      Azizi M, Ezan E, Nicolet L, et al. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/37\">",
"      Cole J, Ertoy D, Lin H, et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000; 106:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/38\">",
"      Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001; 12:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/39\">",
"      Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 1999; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/40\">",
"      Kedzierska K, Kabat-Koperska J, Safranow K, et al. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients. Clin Transplant 2008; 22:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/41\">",
"      Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275:26765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/42\">",
"      Remynse LC, Begun FP, Jacobs SC, Lawson RK. Juxtaglomerular cell tumor with elevation of serum erythropoietin. J Urol 1989; 142:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/43\">",
"      Erkelens DW, Statius van Eps LW. Bartter's syndrome and erythrocytosis. Am J Med 1973; 55:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/44\">",
"      Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/45\">",
"      Cross NB, Webster AC, Masson P, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009; :CD003598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/46\">",
"      Vlahakos DV, Marathias KP, Kosmas EN. Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med 2001; 134:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/47\">",
"      Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/48\">",
"      Herrlin B, Nyquist O, Sylv&eacute;n C. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. Br Heart J 1991; 66:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/49\">",
"      Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005; 45:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/50\">",
"      Odabas AR, Cetinkaya R, Selcuk Y, et al. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003; 45:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/51\">",
"      Ert&uuml;rk S, Nergizolu G, Ate K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/52\">",
"      Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001; 38:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/53\">",
"      Rell K, Koziak K, Jarzyo I, et al. Correction of posttransplant erythrocytosis with enalapril. Transplantation 1994; 57:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/54\">",
"      Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/55\">",
"      Julian BA, Gaston RS, Barker CV, et al. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994; 46:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/56\">",
"      Gross M, Goldwasser E. On the mechanism of erythropoietin-induced differentiation. XIV. The apparent effect of etiocholanolone on initiation of erythropoiesis. Exp Hematol 1976; 4:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/57\">",
"      Zanjani ED, Banisadre M. Hormonal stimulation of erythropoietin production and erythropoiesis in anephric sheep fetuses. J Clin Invest 1979; 64:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/58\">",
"      Nielsen AH, Johannessen A, Poulsen K. Inactive plasma renin exhibits sex difference in mice. Clin Sci (Lond) 1989; 76:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/59\">",
"      Ok E, Ak&ccedil;i&ccedil;ek F, T&ouml;z H, et al. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995; 59:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/60\">",
"      Montanaro D, Groupuzzo M, Boscutti G, et al. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clin Nephrol 2000; 53:suppl 47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/61\">",
"      Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001; 72:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/62\">",
"      Klaassen RJ, van Gelder T, Rischen-Vos J, et al. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997; 64:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/63\">",
"      Midtvedt K, Stokke ES, Hartmann A. Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 1996; 11:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/64\">",
"      Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/65\">",
"      Gossmann J, Th&uuml;rmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/66\">",
"      MacGregor MS, Rowe PA, Watson MA, et al. Treatment of  post-renal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Nephron 1996; 4:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/67\">",
"      Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin JM. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 1998; 11:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/68\">",
"      Barenbrock M, Spieker C, Rahn KH, Zidek W. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol 1993; 40:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/69\">",
"      Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990; 323:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/70\">",
"      Mazzali M, Filho GA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation 1998; 65:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10857/abstract/71\">",
"      Borawski J, Mazerska M, Rydzewski A, et al. Ketanserin: a new perspective in posttransplant erythrocytosis? Clin Transplant 1996; 10:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7348 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10857=[""].join("\n");
var outline_f10_38_10857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25596288\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H719588705\">",
"      RISK FACTORS AND ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H719588281\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264990867\">",
"      ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264991850\">",
"      Phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6423914\">",
"      Antiproliferative agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2063178\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264991067\">",
"      Goals and duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25596288\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10858="Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus";
var content_f10_38_10858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10858/contributors\">",
"     Jacques J Bergman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10858/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/38/10858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/38/10858/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/38/10858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrett's esophagus (BE) is thought to be a complication of longstanding gastroesophageal reflux, resulting in the replacement of the normal squamous lining of the distal esophagus by columnar epithelium containing specialized intestinal metaplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic surveillance is recommended for patients with Barrett's esophagus because of its malignant potential in the hope of detecting dysplasia before it progresses to adenocarcinoma. Esophagectomy has traditionally been recommended for patients found to have high-grade dysplasia or early cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic therapy has been proven to be a safe, effective, and less invasive alternative to surgery for treating such patients.",
"   </p>",
"   <p>",
"    Endoscopic resection (ER) is an endoscopic approach in which the neoplastic epithelium is excised, thus allowing for a definitive histologic diagnosis, while also potentially being curative. ER has been applied not only to Barrett's esophagus with high-grade dysplasia but also to early cancer in which the risk of lymph node involvement or hematogenous dissemination is low enough to justify a relatively conservative approach compared with esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/1-8\">",
"     1-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several studies have demonstrated that ER is safe and effective for complete resection of superficial lesions, and offers the advantage of histopathologic verification [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9-12\">",
"       9-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ablative therapy (eg, photodynamic therapy (PDT), argon plasma coagulation (APC), and radiofrequency ablation (RFA)) allows for treatment of larger areas, but provides no specimen for histopathologic evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Europe and Japan, ER is considered the mainstay of endoscopic management and ablative techniques are mainly used as an adjunct to ER. By contrast, in the United States, ablative techniques are more commonly used.",
"   </p>",
"   <p>",
"    The experience with ER in patients with Barrett's esophagus who have high-grade dysplasia (HGD) or early cancer (EC) is discussed here. Photodynamic therapy, radiofrequency ablation, a general approach to Barrett's esophagus, and other treatment options for superficial esophageal cancer are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link\">",
"     \"Radiofrequency ablation for Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION FOR ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major considerations in the evaluation of patients with Barrett's esophagus who have high-grade dysplasia or early cancer: histopathologic evaluation, the endoscopic work-up, and staging of the lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Histopathologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal neoplasia is usually classified according to the internationally accepted Vienna classification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/13\">",
"     13",
"    </a>",
"    ]. The Vienna classification is based upon the histopathologic evaluation of endoscopically acquired biopsies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Category 1: no dysplasia",
"     </li>",
"     <li>",
"      Category 2: indefinite for dysplasia",
"     </li>",
"     <li>",
"      Category 3: low-grade intraepithelial neoplasia (low-grade",
"      <span class=\"nowrap\">",
"       adenoma/dysplasia)",
"      </span>",
"     </li>",
"     <li>",
"      Category 4: high-grade intraepithelial neoplasia (high-grade",
"      <span class=\"nowrap\">",
"       adenoma/dysplasia,",
"      </span>",
"      noninvasive carcinoma or suspicion of invasive carcinoma)",
"     </li>",
"     <li>",
"      Category 5: invasive epithelial neoplasia (intramucosal carcinoma, submucosal carcinoma, or beyond)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between categories 4 and 5 can be difficult since it depends in part upon the size, location, depth, and number of biopsies. In category 4, there is no obvious invasion beyond the epithelial basal membrane. Category 5 is subdivided based upon whether there is invasion into the lamina propria or muscularis mucosa (category 5.1, also referred to as intramucosal cancer) or into the submucosa (category 5.2, also referred to as submucosal cancer).",
"   </p>",
"   <p>",
"    Another problem with the diagnosis of dysplasia in Barrett's epithelium is the interobserver reliability among pathologists. As a result, it is helpful to achieve a consensus (ie, from more than one pathologist) in categorizing such specimens. A consensus diagnosis has better predictive value regarding prognosis and may revise the original diagnosis, which can have implications for subsequent management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These observations underlie the recommendation that a second, experienced pathologist should confirm the diagnosis of high-grade dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endoscopic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with HGD or EC in Barrett's esophagus should undergo an endoscopic work-up in a center with expertise in evaluating such patients. The reasons for this are threefold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation at a specialized center helps assure that a second, experienced endoscopist can confirm the findings of the initial endoscopy, making a false positive diagnosis less likely. Up to 40 percent of patients who are diagnosed with HGD have no dysplasia at follow-up endoscopies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/16\">",
"       16",
"      </a>",
"      ]. If the diagnosis of HGD is confirmed in biopsies obtained on a separate occasion, the chance of over diagnosis and unnecessary treatment should be reduced.",
"     </li>",
"     <li>",
"      Evaluation at a specialized center permits detection of synchronous lesions elsewhere in the Barrett's esophagus that might otherwise be left untreated. This is especially important if endoscopic therapy is being considered.",
"     </li>",
"     <li>",
"      Specialized centers often have integrated expertise in gastrointestinal pathology, endoscopy, and surgery, and the experience to offer advanced endoscopic techniques such as ER.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early neoplastic lesions in Barrett's esophagus are often difficult to detect with standard video endoscopy. Although a number of techniques have been proposed to increase the accuracy of endoscopic imaging (such as chromoendoscopy, magnification endoscopy, and optical coherence tomography), none is used routinely in clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=see_link\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=see_link\">",
"     \"Optical coherence tomography in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three general rules should be followed in the endoscopic evaluation of patients being considered for ER:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use the best endoscope available",
"     </li>",
"     <li>",
"      Have a vigilant eye for detecting mucosal abnormalities",
"     </li>",
"     <li>",
"      Use a systematic, meticulous approach",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Use the best endoscope available",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution endoscopy may have higher sensitivity for the detection of early BE neoplasia compared with standard video endoscopy systems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Because early BE neoplasia often presents as flat lesions with only subtle mucosal abnormalities, most experts agree that high-resolution endoscopy is the preferred method for the endoscopic evaluation of BE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Have a vigilant eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 80 percent of patients referred for evaluation of HGD or EC without visible abnormalities will have at least one visible abnormality detected in their BE upon endoscopic inspection by expert endoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Although early BE neoplasia generally presents as subtle flat lesions that can be difficult to detect, most state-of-the-art endoscopes are capable of revealing these abnormalities when viewed by highly experienced endoscopists. Thus, familiarity with the endoscopic appearance of early Barrett's neoplasia is essential for its diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Perform a systematic endoscopic inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of gross mucosal abnormalities such as elevations, ulcerations, and nodularities is relatively easy. By comparison, the detection of subtle abnormalities requires a more careful and thorough inspection, making a systematic approach imperative.",
"   </p>",
"   <p>",
"    After intubation of the esophagus, the esophagus should be carefully cleaned to remove any mucus or saliva. Simple water flushes usually are sufficient but spraying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (1 percent) can be helpful if there is excessive or viscous mucus. It is important to suction all gastric secretions to prevent reflux into the esophagus that could interfere with inspection.",
"   </p>",
"   <p>",
"    The endoscope should be gradually withdrawn to examine the BE segment for mucosal irregularities and to describe the extent of BE. One system for doing so uses the validated Prague C &amp; M criteria, which assess the circumferential and maximum extent of the visualized BE segment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/20\">",
"     20",
"    </a>",
"    ]. After initial inspection, the inflated esophagus should be gradually deflated to reveal any irregularities that may have flattened during inflation, making them more difficult to see. Special attention should be paid to the area between 12 and 6 o'clock in the endoscopic view, where the majority of neoplastic lesions are found [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, if a hiatal hernia is present, it is important to inspect the transition of the BE into the hiatal hernia in the retroflexed position, since abnormalities in this area are easily overlooked in the antegrade view.",
"   </p>",
"   <p>",
"    The Seattle biopsy protocol is recommended for mapping Barrett's esophagus with HGD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/22\">",
"     22",
"    </a>",
"    ]. Targeted biopsies are obtained from all visible abnormalities and random four-quadrant biopsies are taken every 1 cm starting from the top of the gastric folds up to the most proximal extent of the BE (squamocolumnar junction).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The importance of random biopsies every 1 cm rather than every 2 cm was demonstrated in a study in 45 patients with BE and HGD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/22\">",
"       22",
"      </a>",
"      ]. The authors calculated that using a standard protocol would have missed 50 percent of cancers that were detected by the 1 cm protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the above observations, inspection and classification of all visible lesions should be followed by biopsies from each visible abnormality and then random four-quadrant biopsies. The biopsies should always start distally, working upwards to minimize bleeding that obscures visualization. We follow the rule \"look longer, biopsy less\" since, in our experience, the diagnosis of HGD or EC can be made in 80 to 90 percent of patients with these lesions by targeted biopsies after a thorough inspection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/23\">",
"     23",
"    </a>",
"    ]. However, random four-quadrant biopsies are still required, since 10 to 20 percent of lesions are missed with targeted biopsies alone.",
"   </p>",
"   <p>",
"    In addition, the American Society for Gastrointestinal Endoscopy has issued guidelines that recommend endoscopic resection for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Staging procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients diagnosed with HGD or EC, other imaging techniques should be considered to evaluate tumor infiltration depth, local lymph node status, and metastatic spread. Endoscopic ultrasonography (EUS) and computerized tomography (CT scan) are the most widely used techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS is the most accurate technique for locoregional staging of esophageal cancer. However, EUS is less reliable for T- and N-staging in patients with HGD and EC than in patients with more advanced esophageal cancer. In addition, accuracy is influenced by the experience of the endosonographer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High frequency miniprobes may improve the accuracy of T-staging compared with standard EUS, but the accuracy of N-staging appears to be inferior to standard EUS because, while it is higher resolution, the visualization is more superficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=see_link\">",
"     \"High frequency catheter endoscopic ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-staging (depth of invasion) &mdash; Differentiating mucosal lesions from lesions infiltrating into the submucosa is much more difficult in BE than in the squamous esophagus for the following reasons [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The crypts and villi present in BE are more heterogeneous than the layered architecture of squamous epithelium.",
"     </li>",
"     <li>",
"      BE neoplasia can be associated with significant inflammatory changes and the presence of a double muscularis mucosae.",
"     </li>",
"     <li>",
"      Most Barrett's lesions are located in the distal esophagus close to the cardia, where EUS interpretation is known to be difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There appears to be limited added value of EUS for determining T-staging once tumor depth has been estimated by endoscopic inspection of the lesion of interest by an expert endoscopist [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N-staging (nodal status) &mdash; In the work-up and staging of patients with early neoplasia, N-staging is of crucial importance, since positive lymph nodes will exclude patients from endoscopic treatment. EUS has a high negative predictive value (&gt;95 percent) for the absence of tumor infiltration into the deeper wall layers and local lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/25\">",
"       25",
"      </a>",
"      ]. Ultimately, however, the best method for assessment of the risk of lymph node involvement is not EUS, but assessment of the depth of infiltration of the lesion after endoscopic resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     CT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of computed tomography (CT) scanning lies mainly in the detection of distant metastases. The risk for distant metastases is very low in patients with HGD or EC who show no signs of deep submucosal infiltration or suspicious lymph nodes on EUS. Thus, the value of CT is limited in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other radiographic modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging techniques, such as positron emission tomography (PET) scanning and magnetic resonance imaging (MRI), do NOT have a role in the work-up of patients with esophageal HGD or EC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Value of endoscopic resection for staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider ER to be both a reasonable treatment option and also the final step in the diagnostic work-up of patients with HGD or EC in BE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one study, interobserver agreement about the presence of neoplasia was significantly better on ER specimens than biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/31\">",
"     31",
"    </a>",
"    ]. This approach is consistent with 2013 guidelines from the American Society for Gastrointestinal Endoscopy that recommend endoscopic resection for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/24\">",
"     24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The most important predictor of lymph node metastasis is the penetration depth of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/33\">",
"     33",
"    </a>",
"    ]. Endoscopic resection of the most suspicious area in the Barrett's segment, followed by histopathologic evaluation of the endoscopic resection-specimen, permits assessment of infiltration depth and estimation of the risk for local lymph node metastasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC RESECTION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of endoscopic resection techniques have been described for the esophagus, primarily for esophageal squamous neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Established techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Endoscopic resection-cap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely practiced endoscopic resection technique for the treatment of Barrett's neoplasia is the endoscopic resection-cap technique after submucosal lifting (",
"    <a class=\"graphic graphic_figure graphicRef62474 \" href=\"UTD.htm?19/13/19667\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74236 \" href=\"UTD.htm?6/60/7111\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The target lesion is first lifted by injection of a fluid, which may be saline or diluted epinephrine (1:100,000), into the submucosal layer. Subsequently, a transparent cap is attached to the endoscope. The cap has a distal ridge that allows positioning of a crescent-shaped endoscopic resection-snare. The lesion is sucked into the cap, thus creating a pseudopolyp that is immediately captured by forcefully closing the pre-positioned endoscopic resection-snare. The lesion is then removed using electrocoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopic resection-caps are available with different diameters and have either a straight or an oblique shape. The largest en bloc resections are achieved with a large caliber flexible cap that, despite its large outer diameter of 18 mm, can be relatively easily introduced into the esophagus due to its flexibility. Using this technique, lesions with a diameter of more than 2 cm can be removed en bloc.",
"   </p>",
"   <p>",
"    An alternative approach (the \"suck-band-and-ligate\" technique) does not require submucosal injection (",
"    <a class=\"graphic graphic_picture graphicRef74236 \" href=\"UTD.htm?6/60/7111\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9\">",
"     9",
"    </a>",
"    ]. A reusable variceal ligation device is used to suck the lesion into the ligation cap, allowing it to be captured with a rubber band. The endoscope is then removed, the ligation device is disassembled, and the endoscope is reintroduced to remove the created pseudopolyp with a standard polypectomy snare.",
"   </p>",
"   <p>",
"    These two techniques were compared in a prospective randomized trial of 100 consecutive endoscopic resections in 72 patients with early stage esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/36\">",
"     36",
"    </a>",
"    ]. Fifty endoscopic resections were performed with the \"suck-band-and-ligate technique\" without prior submucosal injection and 50 resections were done with the endoscopic resection-cap technique after submucosal injection of a diluted epinephrine solution. No significant differences were observed between the two groups with regard to size of the resected specimens (ligation group: 16.4 x 11 mm versus cap group: 15.5 x 10.7 mm). There was one minor episode of bleeding in each group and no severe complications occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Multiband mucosectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiband mucosectomy (MBM) uses a modified variceal band ligator with six bands and a handle that allows passage of a hexagonal snare alongside the releasing wires for the bands. Suction is used to draw the lesion into the cap, a rubber band is deployed, and a polypoid lesion is created. The \"polyp\" can then be removed using a snare that is inserted through the biopsy channel during the procedure, thereby eliminating the need to remove the scope between banding and snare polypectomy. Multiple specimens can be removed during the procedure using this device (",
"    <a class=\"graphic graphic_picture graphicRef53386 \" href=\"UTD.htm?40/63/41972\">",
"     picture 2",
"    </a>",
"    ). A multiband mucosectomy device is now commercially available (Duette&trade;; Cook Medical, Limerick, Ireland).",
"   </p>",
"   <p>",
"    This MBM technique has several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a modification of the \"suck-band-and-ligate technique\", it does not require submucosal injection as with the endoscopic resection-cap technique. The reason is that the esophageal muscle layer will immediately retract when captured within a rubber band whereas, with the standard endoscopic resection-cap technique, it will remain captured in the forcefully closed endoscopic resection-snare.",
"     </li>",
"     <li>",
"      Multiple resections can be performed with the same snare.",
"     </li>",
"     <li>",
"      Pre-looping the endoscopic resection-snare in the ridge of the cap is not necessary.",
"     </li>",
"     <li>",
"      MBM does not require withdrawal of the endoscope between resections as is needed with the \"conventional\" suck-band-and-ligate technique. Since the instrument holds six rubber bands, up to six consecutive resections can be performed. This reduces the time and cost required for the procedure, while also reducing patient discomfort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective",
"    <strong>",
"    </strong>",
"    registration of 243 MBM procedures in patients with BE demonstrated that the technique is safe and effective. Complications occurring during the procedure (acute complications) were observed in 3 percent. Bleeding was the only acute complication, and in all cases it was managed endoscopically. No perforations occurred. Complications within 30 days of the procedure (early complications) included delayed bleeding (2 percent of procedures) that was managed endoscopically and stenosis (48 percent). Endoscopic complete resection was achieved in 91 percent of focal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case control study, 80 MBM procedures were compared with 86 endoscopic resection-cap procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/37\">",
"     37",
"    </a>",
"    ]. The study showed that MBM was safe and effective for widespread endoscopic resection in Barrett's esophagus. MBM appeared to be quicker than endoscopic resection-cap, but the specimens removed with MBM were significantly smaller than with the endoscopic resection-cap technique.",
"   </p>",
"   <p>",
"    Following this case-control study, a multicenter randomized controlled trial was initiated to compare the endoscopic resection-cap technique and MBM for piecemeal resection of early neoplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/38\">",
"     38",
"    </a>",
"    ]. The trial included 84 patients (42 assigned to MBM and 42 to ER -cap) and found that procedure times and costs were significantly less with MBM versus endoscopic resection-cap (34 versus 50 minutes and 240 versus 322 euro, respectively). MBM resulted in smaller specimens than endoscopic resection-cap (18 versus 20 mm in longest dimension). There were no significant differences in maximum specimen thickness or the amount of submucosa resected. There were three perforations in the endoscopic resection-cap group and one perforation in the MBM group. The perforations in the endoscopic resection-cap group were treated endoscopically, whereas the perforation in the MBM group required surgical repair because of periesophageal scarring that prevented endoscopic closure.",
"   </p>",
"   <p>",
"    MBM appears to be safe and fast for widespread ER in Barrett's esophagus. Time and costs appear to be saved compared to endoscopic resection-cap, since submucosal lifting is not required and a single snare can be used for all resections. MBM does not appear to be associated with more complications than endoscopic resection-cap, despite lack of submucosal lifting. MBM results in significantly smaller sized resections, but the clinical relevance of this finding may be questioned, since there was no significant difference in the depth of resection between the two techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     New techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;New endoscopic resection techniques continue to be explored. Japanese endoscopists have used specially designed needle-knives for en bloc dissection of large esophageal lesions, a technique known as endoscopic submucosal dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. These dissection techniques are usually performed after submucosal injection with viscous substances such as hyaluronidate, which provide prolonged submucosal lifting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Experience is limited and a high level of endoscopic expertise appears to be required for their safe application. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'ESD techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the future, different ER techniques may be combined. The endoscopic resection-cap technique or the needle-knife endoscopic dissection technique may be preferred for en bloc removal of focal lesions, while the other approaches may be used for removal of residual mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACID SUPPRESSION FOLLOWING ENDOSCOPIC RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be treated with adequate acid suppression to allow the endoscopic resection wounds to heal with neosquamous epithelium and probably also to reduce local scarring. Most centers treat patients with high dose proton pump inhibitors (we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    40 mg twice daily).",
"   </p>",
"   <p>",
"    The wounds generally heal in three to six weeks depending upon the size of the resected area. No studies have evaluated the mucosal regenerative pattern after ER. In our experience, healing proceeds from proximal to distal with regeneration starting from the edges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATHOLOGIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpreting ER specimens of Barrett's neoplasia may be more difficult than specimens obtained from squamous lesions. The tissue architecture with crypts and villi differs from the layered architecture in squamous mucosa, making it more difficult to discern a clear transition between wall layers. This problem is further increased by the presence of a double muscularis mucosae in many patients with BE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/43\">",
"     43",
"    </a>",
"    ]. Because the deeper muscle layer represents the true muscularis mucosae, lesions infiltrating through the superficial muscularis mucosae should NOT be considered as submucosal invading cancers.",
"   </p>",
"   <p>",
"    To further complicate matters, complete histologic assessment is generally not available during the procedure. As a result, the endoscopist cannot make real-time decisions regarding the adequacy of tissue resection. A pilot study suggested that real-time frozen sections can provide histologic assessment that correlates well with permanent sections, but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many early lesions in BE are associated with severe inflammation that is due to the accompanying reflux disease and may hamper histological assessment. Similarly, because endoscopic resection involves the use of electrocoagulation, the deep and especially the lateral resection margins often have extensive coagulation artifacts, complicating histologic evaluation compared with surgical resection specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability to treat EC with ER underscores the important nuances of histopathologic assessment. However, making important distinctions between HGD and invasive cancer (and its depth of invasion) may not be straightforward. In an illustrative report, the interobserver reliability for distinguishing Barrett's esophagus with HGD from intramucosal cancer in surgical specimens was poor (kappa statistic 0.42) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/46\">",
"     46",
"    </a>",
"    ]. It was somewhat better for distinguishing intramucosal and submucosal cancer (kappa statistic of 0.71).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathologic subclassification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology and classification of early esophageal cancers have evolved and are outlined in the 2010 TNM staging system of the AJCC (American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer)/UICC",
"    </span>",
"    (International Union Against Cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early esophageal cancers are those that are classified as Tis (high-grade dysplasia, which includes all noninvasive neoplastic epithelial that was formerly called carcinoma in situ) or T1 tumors. T1 tumors are further split into T1a and T1b subcategories, depending upon the depth of invasion (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/46\">",
"     46",
"    </a>",
"    ]. However, this classification by itself is inadequate to distinguish differences in lymph node involvement among T1a and T1b esophageal cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more comprehensive subclassification scheme has been proposed for early esophageal cancers and is useful for determining prognosis and selecting treatment (",
"    <a class=\"graphic graphic_figure graphicRef64349 \" href=\"UTD.htm?16/57/17302\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/47\">",
"     47",
"    </a>",
"    ]. According to this classification, mucosal tumors are divided into three types based upon the depth of invasion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M1 &ndash; Limited to the epithelial layer",
"     </li>",
"     <li>",
"      M2 &ndash; Invades the lamina propria",
"     </li>",
"     <li>",
"      M3 &ndash; Invades into but not through the muscularis mucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    M1 tumors correspond to the Tis stage in the AJCC stage definition, while both M2 and M3 tumors would be considered T1a lesions.",
"   </p>",
"   <p>",
"    Tumors invading the submucosa are subclassified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SM1 &ndash; Penetrates the shallowest one-third of the submucosa (&lt;500 microns)",
"     </li>",
"     <li>",
"      SM2 &ndash; Penetrates into the intermediate one-third of the submucosa",
"     </li>",
"     <li>",
"      SM3 &ndash; Penetrates the deepest one-third of the submucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these subcategories would be considered T1b disease according to the AJCC stage definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For Barrett's neoplasia, ER is considered appropriate therapy for lesions limited to the superficial mucosal layers (M1 and M2 tumors) because these tumors have low rates of lymph node metastasis (&lt;3 percent). There is less consensus, however, with regard to lesions that extend to the muscularis mucosa (M3 tumors), yet most centers consider this an accepted indication for endoscopic treatment of early Barrett's neoplasia, whereas for squamous neoplasia M3 lesions are a relative indication.",
"   </p>",
"   <p>",
"    Esophagectomy is generally preferred for lesions that invade the submucosa (SM1, SM2, and SM3 tumors) given the significantly higher rates of lymph node metastasis associated with these lesions (",
"    <a class=\"graphic graphic_table graphicRef59638 \" href=\"UTD.htm?6/40/6797\">",
"     table 2",
"    </a>",
"    ). Some groups have suggested that ER may be appropriate for lesions that penetrate into the superficial submucosal (SM1 tumors with submucosal penetration &lt;500 microns). The reason ER may be an option is that these lesions may have a low risk of positive lymph nodes, provided that they do not show poorly differentiated cancer or lymphovascular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, most centers consider SM1 tumors to be an indication for surgery and reserve ER for patients who are considered to be at high surgical risk. More studies are required before strong management advice can be given with regard to these lesions.",
"   </p>",
"   <p>",
"    The above considerations underscore the importance of specialized referral centers where expert pathologists are available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the efficacy of ER for management of high-grade dysplasia (HGD) or early cancer (EC) in BE is evolving. The available evidence suggests that ER for these conditions has an initial success rate comparable to surgical treatment, but with fewer complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9,12,50-57\">",
"     9,12,50-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger lesions are less suitable for ER since piecemeal resection is often necessary, which requires a higher level of endoscopic expertise, increases the chances of complications, and often makes it impossible to be conclusive about the completeness of the resection at the lateral margins.",
"   </p>",
"   <p>",
"    The rate of complete remission (ie, successful removal of the HGD or EC with ER) is variable, ranging from 59 to 99 percent in different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9,12,50-55,57,58\">",
"     9,12,50-55,57,58",
"    </a>",
"    ]. Higher degrees of success are seen in patients with lower risk lesions, which are defined as macroscopic types I (protruded type), IIa (flat elevated type), IIb (flat type), and IIc (flat depressed type); a lesion diameter up to 20 mm that is limited to the mucosa; and histologically well to moderately well differentiated tumors.",
"   </p>",
"   <p>",
"    Recurrence of carcinoma or the development of metachronous malignancies has been described in 7 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9,12,50-54,56,57\">",
"     9,12,50-54,56,57",
"    </a>",
"    ]. Multiple factors have been associated with recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/12,51,54\">",
"     12,51,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Larger lesion diameter",
"     </li>",
"     <li>",
"      Long-segment BE",
"     </li>",
"     <li>",
"      Removal of the lesion with piecemeal resection",
"     </li>",
"     <li>",
"      Failure to perform adjunctive ablative therapy (photodynamic therapy, argon plasma coagulation, or radiofrequency ablation)",
"     </li>",
"     <li>",
"      Presence of multifocal neoplasia",
"     </li>",
"     <li>",
"      An elapsed time of more than 10 months prior to achieving complete remission",
"     </li>",
"     <li>",
"      The presence of residual dysplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, recurrences were successfully managed endoscopically.",
"   </p>",
"   <p>",
"    The ideal candidate for ER has a solitary, small (ie, &lt;2 cm diameter), flat type lesion (usually a combination of types IIa, IIb, and IIc) that is limited to the mucosa. Histopathologic differentiation may be less important for most cases, since the vast majority of these early lesions will be classified as high-grade dysplasia or well differentiated cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/11\">",
"     11",
"    </a>",
"    ]. Poor or undifferentiated tumor differentiation is a predictor of adverse outcomes in studies using univariate analysis, but these studies usually included patients with more advanced lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multivariate analyses, tumor differentiation has NOT been identified as an independent risk factor for lymph node metastasis or tumor recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/33\">",
"     33",
"    </a>",
"    ]. This finding may be related to the fact that most undifferentiated tumors have already invaded the submucosa at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/11\">",
"     11",
"    </a>",
"    ]. However, reliable data on the relevance of histopathologic differentiation are sparse, especially given the small number of early, undifferentiated lesions in the available studies.",
"   </p>",
"   <p>",
"    An important drawback of ER monotherapy for HGD or EC in BE is the high recurrence rate of 30 percent within five years during follow-up. Endoscopic ablative therapy with photodynamic therapy (PDT) or radiofrequency ablation (RFA) permits treatment of the whole Barrett's segment in one session, which may permit treatment of larger lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be associated with a lower recurrence rate.",
"   </p>",
"   <p>",
"    PDT has been investigated as monotherapy for HGD and EC in BE as well as an adjuvant treatment after ER. Studies of RFA have reported impressive success rates when used in combination with ER for removal of visible abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link\">",
"     \"Radiofrequency ablation for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the risk for recurrence, patients treated with endoscopic resection require regular endoscopic follow-up to detect recurrent lesions. In most studies, patients are followed every three months during the first year and annually thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications with the ER techniques described above are rare, though complications such as stricture formation are common if large areas of Barrett's mucosa are resected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9,58,61,62\">",
"     9,58,61,62",
"    </a>",
"    ]. Studies have shown that the risk of complications increases with piecemeal resection and the degree of involvement of the mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/61,63\">",
"     61,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding occurs in 0 to 46 percent of cases (depending in part upon how it is defined) and can usually be managed easily with endoscopic methods [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/9,52,54,55,62,64\">",
"       9,52,54,55,62,64",
"      </a>",
"      ]. We suggest that immediate bleeding be regarded as a complication only if it results in clinical consequences such as a drop in the hemoglobin level, the need for blood transfusions, or clinical signs of recurrent bleeding after the endoscopic procedure.",
"     </li>",
"     <li>",
"      Perforation has been reported, with an estimated incidence &gt;1 to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. The risk is increased during piecemeal resection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Strictures have been reported in 2 to 88 percent of patients undergoing ER for BE [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/58,61,62,65-68\">",
"       58,61,62,65-68",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       size/length",
"      </span>",
"      of the mucosal defect and the degree of circumferential involvement by the BE predict stricture formation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/61,65\">",
"       61,65",
"      </a>",
"      ]. In a study of 73 patients who underwent endoscopic resection for BE with high-grade dysplasia or intramucosal carcinoma, symptomatic strictures developed in 25 percent. Strictures were more common if the BE involved more than 50 percent of the esophageal circumference (odds ratio 4.2, 95% CI 1.3-14). There was a trend toward tobacco use also increasing the risk (odds ratio 3.3, 95% CI 0.93-12). Strictures arising after ER usually resolve with dilation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FUTURE PROSPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete ER of the whole Barrett's segment (",
"    <a class=\"graphic graphic_picture graphicRef76681 \" href=\"UTD.htm?38/19/39220\">",
"     picture 3",
"    </a>",
"    ) offers the potential to remove the entire area of dysplastic and metaplastic tissue, an approach that we believe has several advantages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It allows complete removal of the whole mucosa at risk for malignant progression.",
"     </li>",
"     <li>",
"      It provides tissue samples for optimal histopathologic diagnosis.",
"     </li>",
"     <li>",
"      It may reduce the risk of hidden glands of Barrett's mucosa remaining buried underneath neosquamous mucosa compared with ablative therapies.",
"     </li>",
"     <li>",
"      It may reduce the likelihood of persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      induced genetic abnormalities that are associated with the progression of BE to adenocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=see_link\">",
"       \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several series have demonstrated the feasibility and safety in experienced hands of ER of the entire Barrett's segment, even in patients with a long segment of BE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/58,69-72\">",
"     58,69-72",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 21 patients with HGD or EC underwent two sessions each of ER to remove the entire Barrett's segment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/71\">",
"       71",
"      </a>",
"      ]. This was performed with a polypectomy snare after a submucosal injection of 10 to 15 mL of saline. There were no severe complications and none of the patients developed a stricture. In three patients, histology revealed that resection of an EC was incomplete; one patient underwent surgery (no residual tumor was found in the surgical resection specimen), and the other two patients underwent chemoradiotherapy. All three were alive without residual disease at follow-up.",
"      <br/>",
"      <br/>",
"      Of the 18 patients with successful eradication of neoplasia, two (11 percent) showed recurrence of HGD during follow-up and were successfully retreated with endoscopic resection. Five patients had residual islands of Barrett's mucosa embedded in the neosquamous mucosa, with low-grade dysplasia present in three of the five.",
"     </li>",
"     <li>",
"      Another series included 39 patients with HGD or EC in BE who underwent radical endoscopic resection using the endoscopic resection-cap technique after submucosal lifting (median of three sessions) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/69\">",
"       69",
"      </a>",
"      ]. All of the Barrett's mucosa was removed in 33 (89 percent) of the patients, four patients had small isles of Barrett's mucosa buried beneath the neosquamous mucosa (all had received argon plasma coagulation), and two could not complete the therapy due to unrelated comorbidities. There were two complications (one asymptomatic perforation and one delayed bleeding) and 10 patients (26 percent) developed dysphagia that responded to dilation. After a median of 11 months follow-up, there were no cases of recurrent neoplasia or Barrett's mucosa.",
"     </li>",
"     <li>",
"      In the largest multicenter series reported thus far, 169 patients with HGD or EC in BE up to 5 cm were treated with stepwise radical endoscopic resection to remove all neoplasia and Barrett's mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?10/38/10858/abstract/68\">",
"       68",
"      </a>",
"      ]. According to an intention-to-treat analysis, complete eradication of all neoplasia and all intestinal metaplasia by the end of the treatment phase was reached in 98 and 85 percent of patients, respectively. One patient had progression of neoplasia during treatment and died of metastasized adenocarcinoma (0.6 percent). After median follow-up of 32 months (interquartile range 19 to 49 months), complete eradication of neoplasia and intestinal metaplasia was sustained in 95 and 81 percent of patients, respectively. Acute, severe complications occurred in 1.2 percent of patients, and 50 percent of patients developed symptomatic stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=see_link\">",
"       \"Patient information: Barrett's esophagus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=see_link\">",
"       \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest endoscopic resection (ER) as an alternative to surgery or ablative approaches in carefully selected patients with high-grade dysplasia or early mucosal cancer complicating Barrett's esophagus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation for eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ER is particularly useful in patients with nodular high-grade dysplasia.",
"     </li>",
"     <li>",
"      ER aids in histopathologic diagnosis, since it permits assessment of depth of infiltration and estimation of the risk for local lymph node metastasis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Value of endoscopic resection for staging'",
"      </a>",
"      above.) On the other hand, histopathologic interpretation of ER specimens may not be straightforward. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathologic assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with high-grade dysplasia or early cancer should be referred to specialized centers that have integrated expertise in gastrointestinal endoscopy, imaging, surgery, and histopathology.",
"     </li>",
"     <li>",
"      The most common complications from ER are bleeding and esophageal stricture formation, both of which can generally be addressed endoscopically. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with ER require regular follow-up to detect recurrent lesions. In most studies, patients are followed every three months during the first year and annually thereafter. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal techniques for performing ER alone or in conjunction with other endoscopic approaches are evolving. New endoscopic resection techniques will probably become available that permit radical resection of the entire affected mucosa. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Future prospects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/1\">",
"      Fernando HC, Luketich JD, Buenaventura PO, et al. Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur J Cardiothorac Surg 2002; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/2\">",
"      Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/3\">",
"      Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg 1999; 117:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/4\">",
"      Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/5\">",
"      Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001; 122:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/6\">",
"      Ruol A, Merigliano S, Baldan N, et al. Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 1997; 10:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/7\">",
"      Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/8\">",
"      van Sandick JW, Baak JP, van Lanschot JJ, et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000; 190:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/9\">",
"      Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/10\">",
"      Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000; 52:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/11\">",
"      Vieth M, Ell C, Gossner L, et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 2004; 36:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/12\">",
"      Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/13\">",
"      Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/14\">",
"      Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/15\">",
"      Hulscher JB, Haringsma J, Benraadt J, et al. Comprehensive Cancer Centre Amsterdam Barrett Advisory Committee: first results. Neth J Med 2001; 58:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/16\">",
"      Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/17\">",
"      Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy 2005; 37:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/18\">",
"      Kara MA, Smits ME, Rosmolen WD, et al. A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastrointest Endosc 2005; 61:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/19\">",
"      Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/20\">",
"      Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C &amp; M criteria. Gastroenterology 2006; 131:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/21\">",
"      Pech O, Gossner L, Manner H, et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007; 39:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/22\">",
"      Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/23\">",
"      Curvers WL, Bergman JJ. Multimodality imaging in Barrett's esophagus: looking longer, seeing better, and recognizing more. Gastroenterology 2008; 135:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/24\">",
"      ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013; 77:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/25\">",
"      Bergman JJ, Fockens P. Endoscopic ultrasonography in patients with gastro-esophageal cancer. Eur J Ultrasound 1999; 10:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/26\">",
"      Fockens P, Van den Brande JH, van Dullemen HM, et al. Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc 1996; 44:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/27\">",
"      May A, G&uuml;nter E, Roth F, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/28\">",
"      Heeren PA, van Westreenen HL, Geersing GJ, et al. Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. Endoscopy 2004; 36:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/29\">",
"      Pouw RE, Heldoorn N, Herrero LA, et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/30\">",
"      Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2005; 62:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/31\">",
"      Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007; 66:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/32\">",
"      Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008; 67:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/33\">",
"      Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004; 60:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/34\">",
"      Inoue H, Fukami N, Yoshida T, Kudo SE. Endoscopic mucosal resection for esophageal and gastric cancers. J Gastroenterol Hepatol 2002; 17:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/35\">",
"      Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endoscopy 2011; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/36\">",
"      May A, Gossner L, Behrens A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/37\">",
"      Peters FP, Kara MA, Curvers WL, et al. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol 2007; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/38\">",
"      Pouw RE, van Vilsteren FG, Peters FP, et al. Randomized trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic resection of early Barrett's neoplasia. Gastrointest Endosc 2011; 74:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/39\">",
"      Yamamoto H, Sekine Y, Higashizawa T, et al. Successful en bloc resection of a large superficial gastric cancer by using sodium hyaluronate and electrocautery incision forceps. Gastrointest Endosc 2001; 54:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/40\">",
"      Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc 2002; 55:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/41\">",
"      Ohkuwa M, Hosokawa K, Boku N, et al. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. Endoscopy 2001; 33:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/42\">",
"      Hirasawa K, Kokawa A, Oka H, et al. Superficial adenocarcinoma of the esophagogastric junction: long-term results of endoscopic submucosal dissection. Gastrointest Endosc 2010; 72:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/43\">",
"      Takubo K, Sasajima K, Yamashita K, et al. Double muscularis mucosae in Barrett's esophagus. Hum Pathol 1991; 22:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/44\">",
"      Prasad GA, Wang KK, Lutzke LS, et al. Frozen section analysis of esophageal endoscopic mucosal resection specimens in the real-time management of Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/45\">",
"      Prasad GA, Buttar NS, Wongkeesong LM, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 2007; 102:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/46\">",
"      Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51:671.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/48\">",
"      Manner H, May A, Pech O, et al. Early Barrett's carcinoma with \"low-risk\" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008; 103:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/49\">",
"      Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/50\">",
"      Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy 2007; 39:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/51\">",
"      Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy 2007; 39:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/52\">",
"      May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/53\">",
"      Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/54\">",
"      Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/55\">",
"      Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol 2009; 104:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/56\">",
"      Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010; 105:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/57\">",
"      Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/58\">",
"      Chung A, Bourke MJ, Hourigan LF, et al. Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy 2011; 43:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/59\">",
"      Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/60\">",
"      Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/61\">",
"      Lewis JJ, Rubenstein JH, Singal AG, et al. Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett's esophagus. Gastrointest Endosc 2011; 74:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/62\">",
"      Gerke H, Siddiqui J, Nasr I, et al. Efficacy and safety of EMR to completely remove Barrett's esophagus: experience in 41 patients. Gastrointest Endosc 2011; 74:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/63\">",
"      Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc 2003; 57:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/64\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/65\">",
"      Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc 2003; 57:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/66\">",
"      Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007; 39:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/67\">",
"      van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/68\">",
"      Pouw RE, Seewald S, Gondrie JJ, et al. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/69\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/70\">",
"      Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003; 57:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/71\">",
"      Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004; 36:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/38/10858/abstract/72\">",
"      Deprez P, Aouattah T, Piessevaux P, et al. Can piecemeal mucosectomy completely remove Barrett's esophagus with high-grade dysplasia or adenocarcinoma? (abstract). Gastrointest Endosc 2005; 61:AB129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2651 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10858=[""].join("\n");
var outline_f10_38_10858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION FOR ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Histopathologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endoscopic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Use the best endoscope available",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Have a vigilant eye",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Perform a systematic endoscopic inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Staging procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - CT scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other radiographic modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Value of endoscopic resection for staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ENDOSCOPIC RESECTION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Established techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Endoscopic resection-cap",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Multiband mucosectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      New techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACID SUPPRESSION FOLLOWING ENDOSCOPIC RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATHOLOGIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathologic subclassification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FUTURE PROSPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2651|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/13/19667\" title=\"figure 1\">",
"      ER Barretts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17302\" title=\"figure 2\">",
"      Depth invasion esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2651|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/60/7111\" title=\"picture 1\">",
"      ER early esoph cancer Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/63/41972\" title=\"picture 2\">",
"      ER HGIN Barretts Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/19/39220\" title=\"picture 3\">",
"      Radical stepwise ER Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/35/4668\" title=\"table 1\">",
"      T stage esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/40/6797\" title=\"table 2\">",
"      Lymph node invasion BE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=related_link\">",
"      High frequency catheter endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=related_link\">",
"      Optical coherence tomography in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/39/2676?source=related_link\">",
"      Patient information: Barrett's esophagus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=related_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_38_10859="Thallium v technetium imaging";
var content_f10_38_10859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of thallium-201 and technetium-99m",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thallium-201",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technetium-99m",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dose",
"       </td>",
"       <td>",
"        2-4 mCi",
"       </td>",
"       <td>",
"        20-30 mCi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photon energy",
"       </td>",
"       <td>",
"        69-83 keV",
"       </td>",
"       <td>",
"        140 keV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Half-life",
"       </td>",
"       <td>",
"        73 hours",
"       </td>",
"       <td>",
"        6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Availability",
"       </td>",
"       <td>",
"        Cyclotron-produced",
"       </td>",
"       <td>",
"        Generator produced; often available on site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant redistribution",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10859=[""].join("\n");
var outline_f10_38_10859=null;
var title_f10_38_10860="Risk factors ectopic pregnancy";
var content_f10_38_10860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Degree of risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        High",
"       </td>",
"       <td>",
"        Previous ectopic pregnancy",
"       </td>",
"       <td>",
"        9.3 - 47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous tubal surgery",
"       </td>",
"       <td>",
"        6.0 - 11.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tubal ligation",
"       </td>",
"       <td>",
"        3.0 - 139",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tubal pathology",
"       </td>",
"       <td>",
"        3.5 - 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In utero DES exposure",
"       </td>",
"       <td>",
"        2.4 - 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current IUD use",
"       </td>",
"       <td>",
"        1.1 - 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Moderate",
"       </td>",
"       <td>",
"        Infertility",
"       </td>",
"       <td>",
"        1.1 - 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous cervicitis (gonorrhea, chlamydia)",
"       </td>",
"       <td>",
"        2.8 - 3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of pelvic inflammatory disease",
"       </td>",
"       <td>",
"        2.1 - 3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sexual partners",
"       </td>",
"       <td>",
"        1.4 - 4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking",
"       </td>",
"       <td>",
"        2.3 - 3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Low",
"       </td>",
"       <td>",
"        Previous pelvic/abdominal surgery",
"       </td>",
"       <td>",
"        0.93 - 3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal douching",
"       </td>",
"       <td>",
"        1.1 - 3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early age of intercourse (&lt;18 years)",
"       </td>",
"       <td>",
"        1.1 - 2.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Ankum, WM, Mol, BWJ, Van Der Veen, F, Bossuyt, PMM. Fertil Steril 1996; 65:1093 and Murray, H, Baakdah, H, Bardell, T, Tulandi, T. CMAJ 2005; 173:905 and Bouyer, J, Coste, J, Shojaei, T, et al. Am J Epidemiol 2003; 157: 185.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10860=[""].join("\n");
var outline_f10_38_10860=null;
var title_f10_38_10861="Etiology of dystonia b";
var content_f10_38_10861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Heredogenerative diseases (continued)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        D. Associated with metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Amino acid disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Glutaric acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Methylmalonic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Homocystinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hartnup's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tyrosinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Lipid disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Metachromatic leukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ceroid lipofuscinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Niemann-Pick type C (dystonic lipidosis, \"sea",
"blue\" histiocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gangliosidoses GM1-, GM2-variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hexosaminidase A",
"and B deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Other metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tyrosine hydroxylase deficiency (chromosome - 21)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Biopterin deficient diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Triosephosphate isomerase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Aromatic amino acid decarboxylase deficiency (dopamine-agonist",
"responsive dystonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Biotin-responsive basal ganglia disease [Ozand et",
"al, 1998]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        E. Unknown inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroacanthocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rett syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraneuronal inclusion disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infantile bilateral striatal necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial basal ganglia",
"calcifications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hereditary spastic paraplegia with dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deletion of",
"18q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        F. Mitochondrial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leigh disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leber disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        G. Due to a known specific cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perinatal cerebral injury and kernicterus: Athetoid cerebral palsy, delayed onset dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection: Viral encephalitis, encephalitis lethargica, Reye's syndrome; subacute sclerosing panencephalitis; Jakob-Creutzfeldt disease; HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other: Tuberculosis, syphilis, acute infectious torticollis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs: Levodopa and dopamine agonists, dopamine receptor blocking drugs, fenfluramine, anticonvulsants, flecainide, ergots, certain calcium channel blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxins: MN, CO, CS2, cyanide, methanol, disulfiram, 3-nitroproprionic acid, wasp sting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic: Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraneoplastic brainstem encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10861=[""].join("\n");
var outline_f10_38_10861=null;
var title_f10_38_10862="Consent hormonal contraception";
var content_f10_38_10862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Informed consent for hormonal contraceptives (the pill, the patch, the ring, Depo-Provera, implant - Implanon, Nexplanon)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"3\">",
"        Patient should circle each \"X\" to indicate that she has read and understood each statement.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         1.",
"        </strong>",
"       </td>",
"       <td>",
"        I have discussed the methods of birth control and have chosen to use hormonal contraceptives (HC).",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         2.",
"        </strong>",
"       </td>",
"       <td>",
"        I understand that HCs are very effective birth control but occasionally women might get pregnant taking it. I know there is less chance of this happening if I use HCs correctly and do not skip or miss taking my doses. I understand I should not begin to take the HC if I am pregnant.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         3.",
"        </strong>",
"       </td>",
"       <td>",
"        I understand that there may be less protection from pregnancy when HCs are taken with some drugs, including drugs to control seizures and certain antibiotics. I understand that I should talk to my doctor about taking any other medicine with HCs.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         4.",
"        </strong>",
"       </td>",
"       <td>",
"        I understand that I need regular check-ups while taking HCs including a physical&nbsp;and&nbsp;pelvic and lab tests.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <strong>",
"         5.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I understand that the chances of developing serious health problems increase with age, and when certain other health risk factors are present such as:",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         Smoking more than 15 cigarettes a day",
"        </p>",
"        <p>",
"         Age 35 or older",
"        </p>",
"        <p>",
"         High blood pressure",
"        </p>",
"        <p>",
"         High levels of blood cholesterol",
"        </p>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <strong>",
"         6.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I understand that HC users have a slightly greater chance than non-users of developing certain serious problems that may become fatal in rare cases, including:",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         Blood clots",
"        </p>",
"        <p>",
"         Stroke",
"        </p>",
"        <p>",
"         Heart attack (to women age 35 or older)",
"        </p>",
"        Liver tumors",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <strong>",
"         7.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I know when taking HCs I should watch for these danger signals:",
"       </td>",
"       <td rowspan=\"3\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         A - Abdominal pain",
"        </p>",
"        <p>",
"         C - Chest pain or shortness of breath",
"        </p>",
"        <p>",
"         H - Headaches that are severe",
"        </p>",
"        <p>",
"         E - Eye problems such as blurring or double vision",
"        </p>",
"        <p>",
"         S - Severe depression",
"        </p>",
"        S - Severe leg pain/swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        and report them immediately to my doctor.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <strong>",
"         8.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I understand that I should not use HCs if I have had, now have, or develop in the future:",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         Blood clots",
"        </p>",
"        Inflammation in the veins (phlebitis)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         9.",
"        </strong>",
"       </td>",
"       <td>",
"        I understand that if I see a doctor for any reason, I should tell him/her that I am on HCs.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <strong>",
"         10.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I understand that some minor reactions to HCs may include:",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         Nausea, vomiting",
"        </p>",
"        <p>",
"         Breast tenderness",
"        </p>",
"        <p>",
"         Weight gain or loss",
"        </p>",
"        <p>",
"         Spotting between periods",
"        </p>",
"        Headaches",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <strong>",
"         11.",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        I understand that in addition to its benefits as a method of birth control some women experience the following benefits from using HCs:",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         Decreased menstrual cramps and blood loss",
"        </p>",
"        <p>",
"         Predictable, regular menstrual cycles",
"        </p>",
"        <p>",
"         Less iron deficiency anemia",
"        </p>",
"        <p>",
"         Less acne",
"        </p>",
"        <p>",
"         Some protection from ovarian and uterine lining cancer",
"        </p>",
"        <p>",
"         Decreased risk of infection of the pelvis, uterus, or tubes (PID)",
"        </p>",
"        Fewer ectopic pregnancies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         12.",
"        </strong>",
"       </td>",
"       <td>",
"        I understand that HCs do not protect me from getting STIs (sexually transmitted infections) and it is recommended that condoms be used to do this.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <strong>",
"         13.",
"        </strong>",
"       </td>",
"       <td>",
"        I know that if I have any questions or problems a provider is available to me by phone or in the emergency department.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Additional item for transdermal patch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        I understand the benefits and risks of the patch and that the United States Food and Drug Administration (FDA) believes it is a safe and effective method when used according to the labeling.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Additional items for Depo-Provera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        I understand rare cases of low bone density (weakening bone strength) including bone fractures have been reported in women taking the Depo-Provera shot. For this reason, the FDA states that the shot not be taken for more than two years continuously unless other appropriate methods are not available. I have been encouraged to take calcium daily.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        I understand that the Depo-Provera shot may cause significant weight gain only if I have a tendency to gain weight. I understand that if I have chosen this method, I have been encouraged to exercise and watch my eating habits.",
"       </td>",
"       <td>",
"        <strong>",
"         X",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: the form used by Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10862=[""].join("\n");
var outline_f10_38_10862=null;
var title_f10_38_10863="Pulmon stenosis CW Doppler II";
var content_f10_38_10863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary valve stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The continuous wave Doppler shows a peak systolic velocity across the pulmonary valve of 4.5 m/sec or a gradient of 81 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_38_10863=[""].join("\n");
var outline_f10_38_10863=null;
